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ABSTRACT 
 
Identification and Characterization of Bovine Pol III Promoters to Express a Short-
Hairpin RNA. (December 2010) 
Michael David Peoples, B.S.; B.S., Oregon State University 
Chair of Advisory Committee: Dr. Mark Westhusin 
 
The use of molecular biology as a means to advance agriculture has proven beneficial in 
many fields.  However, the development lentiviral vectors that utilize a livestock 
promoter to express short hairpin RNA (shRNA) has been limited to date.  The goal of 
this research project was to develop and characterize lentiviral bovine Pol III mir30 
shRNA expression vectors for future use in livestock research.  The bovine Pol III 
promoter (7sk, U6-2, or H1) was inserted directly upstream of a mir30 shRNA 
expression sequence in the lentiviral vector pNef-GT.   A transient luciferase knockdown 
assay in human embryonic kidney (HEK) 293T cells was used to compare the 
functionality of these vectors.  The bPol III mir30 shRNA expression vector was co-
transfected with the pGL3 luciferase expression vector and the renilla expression vector 
pLB at a ratio of 5:10:1 respectively.  The vectors were allowed 48 hrs to produce their 
respective products before luciferase activity was measured with the Stop-n-Glo Assay 
(Promega).  Each bPol III promoter was able to express a functional shRNA resulting in 
a reduction of luciferase activity greater than 68%.  The bH1 and bU6-2 Luc shRNA 
vectors were the most effective vectors when transfected with >76% (p-value <0.05) 
 iv 
reduced luciferase activity.  To confirm that these promoters were functional after 
integration into a bovine genome, recombinant lentivirus was made from these vectors.  
These particles were then used to transduce a bovine kidney (MDBK) cell line that 
expressed luciferase.  After transduction, transgenic cells were selected by the addition 
of the antibiotic, Geneticin to the culture media until a population of 100% bPol III 
expression cells were observed for two passages and luciferase activity was measured.  
The 7sk promoter was the most effective bPol III promoter that reduced luciferase 
activity in these cells by 72% (p-value <0.05), while the bU6-2 and bH1 were 
moderately effective at reducing luciferase levels (37%, 46% respectively).  These 
experiments were the first to quantify the bovine Pol III promoter function after 
integration into a bovine genome.  While variability was observed, for livestock based 
research, the b7sk lentiviral vector appears to be the best choice to express a shRNA 
from the genome of a bovine genome. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
RNA interference (RNAi) is an evolutionary conserved gene silencing mechanism found 
in plants, insects, and mammalian cells.  The primary function of this pathway is to 
mediate the targeted reduction of gene products by translational inhibition, or mRNA 
degradation.  In the laboratory, the RNAi pathway has proven to be a powerful tool for 
manipulating protein expression and studying gene function[1].  In addition, it has been 
used to develop model animals with increased muscle mass, and increased resistance to 
viral infections [2, 3].  Harnessing the potential of RNAi could be particularly beneficial 
in the animal agricultural field where creating gene knock-out specimens is more 
difficult than the common rodent model.  Utilizing the RNAi pathway has contributed to 
the knowledge of physiological pathways in animal agriculture [4, 5].  In addition, it has 
been used to develop animals with the potential to be resistant to Transmissible 
Spongiform Encephalopathy [6], commonly known as Mad Cow Disease in cattle.  Also 
RNAi has been used to decrease expression of porcine endogenous retroviruses [7], 
which are a key concern for the use of swine as organ donors in xenotransplantion 
experiments.  Overall, the potential of utilizing RNAi in livestock research and 
production seems limitless.   
____________ 
This thesis follows the style of BMC Biotechnology. 
2 
 
 
Another potentially powerful tool in transgenic animal agriculture research is the 
utilization of lentiviruses to permanently integrate DNA sequences of interest into the 
genome of cells or zygotes.  Lentiviruses are a subfamily of retroviruses that efficiently 
introduce their genome into infected cells.  Through the use of multiple plasmids 
providing essential proteins and RNA sequences, these highly infective viruses have 
been manipulated to be relatively safe for laboratory research.   They have been 
manipulated to be replication incompetent, infect dividing and non-dividing cells and 
integrate a transgene that can be designed in the laboratory [8, 9].  The use of these 
recombinant lentiviruses results in the stable integration of a transgene of interest, which 
can be subsequently passed on to daughter cells and germ cells when used to develop 
transgenic animals.  As a result of these qualities, the use of recombinant lentiviruses to 
transduce zygotes is a promising efficient method to introduce a gene of interest to 
create transgenic livestock [10].   
 
A major goal of our laboratory is to use lentiviral transgenesis and the RNAi pathway to 
develop transgenic livestock with enhanced production characteristics.  Since the 
domestication of animals, humans have been trying to enhance production from different 
desired traits.  These traits include: meat production, milk production, wool or fur, and 
resistance to diseases.  Selective breeding and artificial reproductive technologies are 
most commonly used to enhance these traits.  However, the increase in production is 
minimal from generation to generation when using standard breeding practices.  In 
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addition, selective breeding can lead to the reduction of genetic variation and loss of 
potentially valuable traits from the population.  Researchers have tried to directly 
increase these production traits, as well as introduce others by inserting genes into 
livestock genomes to create transgenic animals [11-15].  These animals were produced 
with hopes of increasing muscle mass, enhancing milk and wool production, as well as, 
producing pharmaceuticals.  Recently, the potential of creating transgenic animals which 
utilize the RNAi pathway to obtain the desired phenotype has been explored to enhance 
livestock production traits.  The enhanced production characteristics our laboratory is 
interested in include increased muscle development and enhanced resistance to 
agricultural viruses.   
 
There are three basic questions that require further research in the production of animals 
that utilize exogenous RNAi precursors to modulate gene products, particularly in 
animals other than rodents.  First, which RNAi precursor is the most effective at 
decreasing only the targeted gene product or products and does not affect other 
physiological pathways. Some of these concerns are off-target effects of the siRNA and 
triggering innate immune responses [16, 17].  Another question to address, are which 
expression cassettes for RNAi precursors are best suited for the desired goals of the 
research.  The majority of the promoters utilized are responsible for natural transcription 
of different housekeeping genes, unfortunately some of these promoters vary in function 
between cell types and stages of animal development [18].  A promoter can be too strong 
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at driving expression of the RNAi precursor which overloads the endogenous RNAi 
pathway and decreases the ability of RISC to perform its normal cellular functions [19].  
In addition, if a RNAi precursor in a specific tissue is desired, specific promoters must 
be identified and tested.  Overall, the ability of the promoter to express sufficient 
amounts of the RNAi precursor that results in a biological effect in all desired tissues is 
the primary goal. The third question is how to efficiently introduce a expression cassette 
into the genome that is functional in a transgenic animal.  Currently, the primary 
methods to produce transgenic animals use pronuclear injection of a gene construct, or 
somatic cell nuclear transfer (SCNT) of genetic material from a manipulated cell line, or 
recombinant retroviruses to deliver a transgene that contains the expression cassette.  
Each of these methods has pro’s and con’s, but the primary limiting factor is the 
efficiency of producing a non-rodent transgenic animal.  While transgenic livestock 
expressing RNAi precursors have been developed, further research is required to 
determine methods that result in a greater efficiency of producing transgenic livestock 
that have the desired levels of gene product knock-down.          
                   
The goal of this research was to focus on the expression of an RNAi precursor and 
identify efficient promoters to express the RNAi effector molecule both transiently and 
after integrated in the genome.  The purpose of this research project was to identify and 
analyze the ability of three bovine Pol III promoters to express an RNAi effector 
molecule (short hairpin RNA) in human and bovine cells.   
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RNA Interference 
The first observations of RNA having an inhibitory role were noted in the early 1980’s.  
When introduced into the cell, antisense RNA resulted in decreased gene and protein 
expression in animal and plantmodels [20-23].  Later, Napoli et. al. in 1990 attempted to 
alter flower color in a petunias with over-expression of a transgene for Chalcone 
synthase (CHS), the protein responsible for pink or violet coloring.  Surprisingly, they 
noticed a significant decrease in flower color that was correlated to a block in the 
anthocyanin biosynthesis or decrease of CHS.  At the time, it was believed that the 
antisense RNA would hybridize with the coding mRNA resulting in double-stranded 
RNA (dsRNA) which either inhibited translation or was targeted for destruction by 
cellular ribonucleases.  It wasn’t until 1998 when Fire and Mello set out to study the 
requirements for structure and delivery of interfering RNA that they discovered dsRNA 
was significantly more effective than targeting single stranded RNA[24].  For these 
experiments, they injected 500-1,000 bp sense, antisense, or mixed (sense+antisense) 
RNA sequences corresponding to mRNA for four different proteins in Caenorhabditis 
elegans that result in observable phenotypes when the protein is not present.  To their 
surprise, the sense or antisense injections only had a marginal effect.  However, when 
the two strands were co-injected creating dsRNA, the greatest phenotypic traits were 
observed and some of the characteristics proceeded through multiple generations.  Their 
data was the first publication proving that dsRNA is responsible for gene product knock-
down.  This achievement was rewarded in 2006 as Craig Mello and Andrew Fire were 
awarded the Nobel Prize in Physiology or Medicine.  In addition, this research provided 
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the foundation for further research into how dsRNA interferes with protein production 
and thus, the RNA-mediated interference (RNAi) field was born.   
 
The RNAi Pathway 
Following the discovery of potent dsRNA mediated interference; the next goal of 
researchers was to determine the effector molecule.  Researchers hypothesized that the 
antisense RNA sequence acts as the guide strand for specific post-transcriptional gene 
silencing (PTGS).  However in the early studies, the full length antisense RNA was 
never detected in hybridization assays.  As a result, Hamilton and Baulcombe set out to 
determine the size of the antisense RNA (effector molecule) that resulted in the gene 
specific knockdown [25].  They transformed tomato plants and analyzed them for PTGS 
of the target protein 1-aminocyclopropane-1-carboxylate oxidase (ACO).  In the selected 
plants that exhibited reduced levels of ACO, they purified low molecular weight nucleic 
acids and used a labeled ACO sense RNA probe to detect the anti-sense RNA.  In their 
findings a high level of antisense RNA approximately 25 nucleotides long was observed.  
To confirm these findings, an antisense 25 nucleotide RNA sequence targeting green 
fluorescent protein (GFP) was developed and transformed into GFP positive leaves.  
Reduced levels of GFP as well as the 25 nt targeting RNA were observed in only the 
transformed leaves.  As a result of this research, they determined the RNAi effector 
molecule is approximately 25 nt.  Supporting these findings, Hammond et. al, used 
Drosophila melanogaster cell extracts and also confirmed the presence of an RNA 
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effector product of ~25 nt [26].  To further confirm the size of the effector molecule, 
Zamore et. al, determined that radiolabeled dsRNA is cleaved into 21-23 nt fragments 
[27].  As a result of these studies, the effector RNA molecule resulting in specific PTGS 
has been determined to be 21-23 nt long.  
 
In addition, to determining the size of the effector molecule, these early studies also 
confirmed that the sequence specific nuclease activity was protein and ATP dependent.  
Hammond et. al, named the enzyme that co-precipitated with the targeting RNA the 
effector protein or later RNA-induced silencing complex (RISC) [26].  The next logical 
question was to determine if this complex was responsible for both the processing of the 
dsRNA into small interfering RNA (siRNA) and subsequently PTGS [28].  They used 
ultra-centrification as a means to fractionate the drosophila cell lysates.  The PTGS 
activity could be removed during this process within the pellet.  However, the protein 
responsible for the processing of the dsRNA into 22 nt products was in the supernatant.  
As a result, they analyzed candidate RNase III proteins based upon the knowledge that 
the processing of the dsRNA trigger into the 22 nt siRNA required ribonuclease activity 
and specificity to bind dsRNA.    A drosophila protein (CG4792) was found to 
consistently process dsRNA into 22 nt products and was subsequently named Dicer..    
These initial findings of the RNAi pathway determined that Dicer, was responsible for 
the cleavage of the trigger dsRNA into an siRNA approximately 21-23 nt in length and 
the effector protein, RISC, was required for siRNA mediated mRNA degradation. 
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As with many important pathways, understanding of the multi-protein complexes 
became a priority.  One particular interest was determining the protein responsible for 
the cleavage of the mRNA after the binding of the RISC.  The RISC complex was 
immunoprecipitated to study the components of the complex.  As a result of these 
studies two proteins were identified Argonaute 1 and Argonaute 2 (Ago 1 and Ago 2).  
Eventually, it was proven that Ago 2 exclusively retained the cleavage ability observed 
during PTGS.  Thus, Ago 2 is the catalytic enzyme responsible for mRNA cleavage by 
RISC in eukaryotic cells.   
 
With a better understanding of the downstream processing of dsRNA and hundreds of 
naturally occurring endogenous small RNA products subsequently discovered, termed 
micro RNA (miRNA).  The question of the nuclear pre-processing was still unanswered.  
Previously, it was found that miRNAs are transcribed as primary transcripts (pri-
miRNAs) and later processed into a stem-loop pre-miRNA structure approximately 70 
bp in length.  Lee et. al, used the miRNA30 as a candidate pre-miRNA[29].  They 
determined that it had a 3’ overhang of 2 nt, suggesting RNase III activity.  As a result of 
these findings, human protein databases were analyzed and three RNase III enzymes 
were found.  One of these proteins, Drosha was known to be localized in the nucleus.  
Further analysis of this protein revealed that it was responsible for creating dsRNA 
products approximately 70 nt in length.  Subsequently, it has been determined that 
Drosha is the nuclear initiator protein of the RNAi pathway.       
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Both miRNA and siRNA result in a reduction of gene products by similar means in the 
RNAi pathway, but vary in origin and action.  A miRNA is generated within the cell, 
and the sequence is highly conserved.  It is rarely perfectly complementarily with 
mRNA sequences, but it can affect protein translation and mRNA decay by binding to its 
imperfectly matched target sites of a mRNA.  A siRNA is usually generated from the 
cleavage synthetic or exogenous dsRNA by Dicer into ~21-nt in size.  Then the targeting 
strand is preferentially loaded into the RISC complex with Ago2.  This complex then 
cleaves its target mRNA if it is perfectly complementarily.  A siRNA can act like a 
miRNA if the loaded RISC binds an imperfect complentary mRNA sequence and results 
in translational inhibition.  In addition, if the targeting strand from a miRNA in theRISC 
complex binds a perfectly complementary sequence, then it can act as a siRNA and 
result in the degradation of the mRNA.  While a siRNA and miRNA may both be similar 
and result in PTGS, they are different.      
 
The RNAi pathway has been found to be highly conserved among many eukaryote cell 
types (Fig. 1).[30].  Initially, the primary miRNA is transcribed in the nucleus.  Then 
drosha recognizes a specific binding sequence and structural elements to direct the 
nuclease activity of the enzyme resulting in a 2 nt 3’ overhang.  This 70 nt stem-loop 
structure is exported to the cytoplasm where the loop is removed by Dicer.  Thus, 
creating a miRNA approximately 22 nt in length.  The anti-sense or guide strand is 
preferentially loaded into the RNA-induced silencing complex (RISC), while the  
10 
 
 
  
Fig. 1. RNAi Pathway.  There are various dsRNA structures that can enter the RNAi 
pathway for processing and resulting in decreased gene expression.  Within the nucleus, 
dsRNA triggers can be expressed from transfected plasmids, or from the genome as 
naturally occurring pre-miRNA or as shRNA from transgene introduced by retroviral 
transgenesis.  Typically these triggers form a stem-loop structure as part of a mRNA 
sequence.  The stem-loop structure is cleaved from the mRNA by the protein Drosha 
then shuttled into the cytoplasm by the protein Exportin V.  Once in the cytoplasm, the 
dsRNA RNA is recognized by Dicer, which cleaves the 22 bp dsRNA from the stem-
loop structure, turning it into an siRNA.  Also within the cytoplasm, other RNAi triggers 
are recognized as dsRNA Fig.and processed by Dicer into small 21-23 nt siRNAs.  In 
addition, synthetic siRNA can be transfected into the cells.  Then the guide (mRNA 
complimentary) strand of the miRNA/siRNA is preferentially loaded into RISC where it 
seeks out complimentary mRNA sequences.  If the exact sequence is recognized, the 
RISC protein directs mRNA cleavage.  However, if a near complimentary sequence is 
recognized (i.e. miRNA or off-target siRNA) RISC mediates translational inhibition.   
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passenger strand is degraded.  The RISC is responsible for recognizing the near 
homologous regions of the mRNA for sequence specific gene silencing. A miRNA 
loaded into the RISC recognize near perfect homologous sequences and result in 
translational repression [31].  Both siRNA’s and miRNA’s are effective tools to inhibit 
protein expression.  However as research continues, the functions of si/miRNA’s 
continue to diversify and have roles in enhancing transcription, increasing gene 
expression, and even altering chromatin and centromeric structure [32, 33].  While more 
new and surprising roles of these small RNA’s are discovered every day, their robust 
ability to decrease gene expression still remains their primary use in the laboratory.      
 
Triggers of the RNAi Pathway     
In the laboratory, dsRNA or triggers of the RNAi pathway can be introduced as many 
forms into cells.  Initially, long targeting sequences (>30 nt) of dsRNA corresponding to 
the target gene of interest were used to mediate the PTGS [34].  These proved to be very 
effective in many models and various gene products.  The long dsRNA homologous to 
the target mRNA is cleaved by Dicer into various siRNAs of 21-23 nt in length.   As a 
result of this random processing, some of the siRNAs would be effective at reducing the 
target gene of interest.  However in mammalian cells, long dsRNA sequences have been 
shown to induce an interferon response [35, 36].  Another negative use of long dsRNA is 
the possibility of off target effects [37].  Many gene sequences share homology, 
especially in gene families with  similar conserved actions.  Consequently, due to the 
12 
 
 
random siRNA sequences created by Dicer, some of these siRNAs could target the 
conserved regions resulting in undesired protein knockdown.  As a result of these 
findings and advancements in RNAi research the use of long dsRNA has been 
substituted with the use of synthetic siRNAs. 
 
Since the discovery of the RNAi pathway, research has evolved to effectively utilize 
synthetic siRNAs as tools for rapid gene product knockdown.   However, the 
effectiveness of a siRNA does not only depend upon homologous sequence binding with 
a target mRNA.   Multiple siRNAs targeting different regions of the same mRNA can 
have various levels of knockdown.  As a result, researchers have compiled extensive 
data sets that included nucleotide composition, length, secondary structure, sugar 
backbone, and sequence specificity of functional si/miRNA.  Computer analysis of the 
characteristics of the guide strand and the mRNA sequence are used to determine 
optimal RNAi target sites [38].  Some general rules have been employed to enhance a 
siRNA’s effectiveness.  One is that the antisense sequence should be 19 nt in length.  
Another is the 3’ end of guide strand should contain two uridine residues.  In addition, to 
increase the efficiency, the siRNA should have a 5’-phosphate group as well as a 3’-
hydroxyl group [39].   Unfortunately even with these rules and the extensive data 
analyzed, the algorithms are not perfect at providing a single optimum siRNA.  As a 
result, the suggested siRNAs should be used as a sampling of target sites within mRNA 
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sequence, and it is up to the researcher to determine the most effective for their 
experiments.    
 
A siRNA is a desirable tool for a knockdown experiment to better understand the 
function or eliminate the presence of a gene product.  Because of their small size, they 
can effectively enter a cell by various transfection methods.  Time is another benefit of 
using synthetic siRNAs, within hours of the transfection the concentration of siRNAs are 
to a point to elicit an effect.  Once inside the cell, the siRNA can be directly loaded into 
RISC.  However, a synthetic siRNA based experiment is also limited by time because 
eventually the transfected population of siRNAs reduces to a critical level where their 
effect diminishes.  This is typically 3-5 days depending upon the gene product [40].  As 
a result, most experiments can be concluded in two days and the knockdown of the gene 
product can be analyzed.  However, if a protein is highly stable, the biological effect can 
outlast the mRNA reduction.  As a result, researchers must be aware of the products they 
are analyzing and modify the experiment time to compensate.    This experimental 
period is shorter than the weeks, months, or even years required when using gene-
knockout technology to analyze protein function.  In addition, if the siRNA target region 
is conserved, the same siRNA can be used to analyze protein knockdown in different 
species.  A drawback to a siRNA experiment is cost.   Even with advancements in 
oligonucleotide synthesis the costs of synthetic siRNA are still relatively high for 
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extensive testing and utilization. However, siRNAs are ideal for many research studies 
where quick analysis of a gene/protein knockdown is desired.  
 
While the use of a synthetic siRNA has many benefits, they are still costly for many 
preliminary experiments and some experiments require a longer inhibition of gene 
products.  As a result of these limitations, alternative means for expressing siRNAs from 
plasmids were explored.  Plasmids actively reproduce their siRNA precursor in the cells 
for weeks or even months.  This continuous production results in an effective population 
of siRNA for a longer period than synthetic siRNAs.  This quality allows an observed 
knockdown for a longer period of time when compared to synthetic siRNA.  When 
comparing costs, DNA oligo sequences corresponding to the siRNA product can be 
ordered and cloned into the expression plasmid for a fraction of the cost when compared 
to synthetic siRNAs.  In addition, once the expression plasmid is created it can be readily 
replicated in the lab for a relatively low cost.  Because of the costs and longer 
expression, the use of plasmids to express a precursor of the siRNA has become a 
powerful tool in RNAi research.   
 
With a better understanding of the RNAi pathway various dsRNA triggers have been 
developed to be expressed from a plasmid.  There are four main types of siRNA 
precursors that have been used (Fig. 2).  One trigger developed directly mimics the 
siRNA and does not require the early processing as other triggers (Fig. 2.A).   Two Pol 
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III promoters separately transcribe either the sense or antisense RNA strand, and the 
RNA products hybridize to form the siRNA [41].  Another trigger developed was the 
short hairpin RNA (shRNA) (Fig. 2.B)[42].  The shRNA is transcribed as a single sense-
loop-antisense RNA sequence that forms a tight hairpin structure with a 3’ TT overhang.  
The targeting sequence (anti-sense) is only 20-23 bp resulting in a siRNA after removal 
of the loop structure by dicer.  The loop sequence does not appear to be important in the 
efficiency of shRNA processing.  Sequences have been successfully used that are 
between 4-9 bp in length.  However, the most commonly used sequence is 5’-
UUCAAGAGA-3’ [42].  Another variation of the shRNA trigger is to mimic an 
endogenous miRNA structure, where the 22 bp sense and antisense sequence is replaced 
with the desired siRNA sequence while the other bumps and loop of the miRNA are 
maintained (Fig. 2.C) [43, 44].  Research has shown that triggers that enter the RNAi 
pathway through a more natural route, like the miRNA based shRNA, result in a more 
effective knockdown.  Another effective trigger expressed from a plasmid is a long 
hairpin RNA (lhRNA) (Fig. 2.D).  The lhRNA structure comprises of a long sense and 
targeting antisense sequence (30-90 bp) with a loop structure between [45].   In the 
cytoplasm, this long dsRNA structure is randomly processed by dicer resulting in 
multiple different siRNA effector molecules.  A lhRNA can be designed to target 
multiple mRNA targets or have all of the random siRNAs targeting a single mRNA.  
However, because of the random processing of dicer, off target affects are harder to 
predict [37].  As well, in mammalian cells, lhRNA have a greater chance of inducing an 
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immune response.  For many research projects utilizing either a basic shRNA or a mir-
based shRNA are ideal.     
 
Promoters to Express RNAi Effector Molecules 
As the popularity of using plasmids for RNAi based research increased, promoters were 
evaluated for their ability to express functional siRNA triggers.  There are two classes of 
promoters used for constitutive expression of RNAi triggers based upon the RNA 
polymerase they recruit.  One class recruits the Pol II promoter.  These promoters have 
typically been used to express a mir-based shRNA, or tissue specific, or inducible 
shRNA expression.  The other type of promoter used, recruits a Pol III polymerase.  
These promoters have been typically used to express very precise sequences like those 
required in the sense-antisense hybrization siRNA expression plasmid or a basic shRNA.  
While both types of promoters are commercially available, neither a Pol III nor Pol II 
promoter has been found to be superior.  It is primarily up to the researcher to determine 
if a Pol III or Pol II of promoter will work best for their research studies.    
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Fig. 2.  Examples of RNAi Triggers.  A. The sense and antisense strands corresponding 
to the siRNA complex are driven by individual Pol III or T7 promoter. B. A single Pol 
III promoter drives the transcription of a DNA sequence corresponding to the sense 
strand, a 4-9 bp loop (non-complimentary) sequence, and antisense strand.  Immediately 
following this DNA sequence are 5-7 thymines that result in the termination of 
transcription. C. A single Pol II promoter drives the transcription of a long transcript that 
includes a fluorescent marker, as well as, an endogenous miRNA sequence where the 
effective siRNA sequence is replaced by a design siRNA sequence. D. A single Pol III 
promoter drives the transcription of a stem loop structure.  However the sense strand is 
longer than 22 bp, which results in multiple siRNA products when the dsRNA is cleaved 
by Dicer.  
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Many different promoters have been effectively used to knockdown gene products.  Pol 
II promoters were initially utilized to mimic endogenous miRNA expression [46].  Pol II 
promoters are responsible for the majority of mRNA transcription, miRNAs, and 
naturally transcribe long sequences.  In shRNA expression plasmids, the Pol II 
polymerase was used to transcribe a long mRNA sequence that included the gene for a 
fluorescent marker as well as the mir-based shRNA in the same transcript [47].   This 
combination of expression is desirable because the fluorescence can be directly 
correlated to shRNA transcription.  Early studies used the human cytomegalovirus 
immediate-early (CMV) promoter to express a mir-based shRNA[48, 49].  However, 
some experiments suggested that the promoter is too effective and elicits an interferon 
response in some cells.  Another Pol II promoter that also has been frequently used for 
plasmid based shRNA expression is the human ubiquitin C promoter [50].  More 
recently, the elongation factor 1-α (EF1-α) promoter has been utilized in commercial 
mir-based shRNA expression vectors.  The EF1-α promoter expresses the alpha subunit 
of the EF-1 complex.  This housekeeping complex is responsible for the enzymatic 
delivery of tRNAs to the ribosome [51].  The EF1-α promoter has been very effective for 
in vitro based RNAi experiments [18].  The majority of the shRNA expression plasmids 
in our laboratory use the EF1-α promoter to express a fluorescent protein and a mir-
based shRNA as a single transcript.  Another Pol II promoter that has been increasingly 
used is the CAG promoter.  This promoter is unique in that it was developed by 
combining the CMV early enhancer element, with the chicken beta-actin promoter, and 
the first intron of chicken beta actin [52].  The combination of these elements has 
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resulted in a very strong promoter that is active in many cell types.  Many Pol II 
promoters are successfully utilized in the commercially available mir-based shRNA 
expression vectors and further research is required to determine which will work best for 
the desired experiments.    
 
However, some experiments are interested in tissue specific or inducible shRNA 
expression.  As a result, many Pol II tissue specific promoters have been explored to 
locally express a shRNA [53, 54].  Other experiments might require expression of a 
shRNA at a certain time or stage of development.  Because of this, inducible promoters 
also have been developed to express a shRNA from a plasmid [50, 55, 56].  Two types 
of inducible elements are commonly used with a Pol II promoter in shRNA expression 
vectors.  One depends on a Cre-Lox recombination reaction to induce expression of a 
shRNA.  Where in the presence of the recombinase Cre, an inhibitory sequence is 
removed that then allows the expression of the shRNA.  Another type of inducible 
shRNA expression vector has  inducible elements in the promoter that are tetracycline 
dependent for activiation/suppression of the promoter to initiate or suppress expression 
of a shRNA.   Research is continuing to advance, improve, and diversify expression of a 
shRNA from Pol II based shRNA expression plasmids.              
 
While Pol II promoters were explored to mimic the miRNA pathway and produce long 
transcripts, Pol III promoters have also been used to express precise shRNA sequences.  
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These are effective because they are used to transcribe small nuclear RNAs that are 
required for normal cellular function.  As a result, their activity should be consistent 
among cell types.  Also, Pol III promoters have a well defined transcriptional start site 
and termination sequence of 5-7 consecutive thymines. Because a Pol III promoter has 
the ability to transcribe a precise transcript constitutively among many cell types they 
have been extensively used in shRNA expression vectors.   
 
Three Pol III promoters have been widely used for the expression of a shRNA from a 
plasmid.  The first Pol III promoter used to express a shRNA was the human U6 small 
nuclear RNA (snRNA) promoter.  The snRNA is the noncoding component of the U6 
small nuclear ribonucleoprotein.  This housekeeping ribonecleoprotein is required for 
pre-mRNA processing.  When the U6 promoter was used to express a shRNA, it resulted 
in the effective knockdown of firefly luciferase and neuron specific β-tublin [57].  The 
U6 promoter has become one of the most popular Pol III promoters on commercially 
available shRNA expression vectors.  Another frequently used promoter is the H1 RNA 
promoter [58].  The H1 protein is a subunit of the Ribonuclease P (RNase P) complex.  
RNase P is a ribozyme responsible for the modifications of tRNA molecules, and plays a 
role in Pol III transcription.  A unique advantage of the H1 promoter is the short 
effective promoter region,only ~100 nt are required to recruit a Pol III polymerase, as 
compared to 350 nt for the U6 promoter region.  A third promoter t used for shRNA 
expression in many plasmids is the 7SK RNA promoter [59-61].  7SK RNA has been 
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found to be an inhibitory protein that binds elongation factor P-TEFb.  P-TEFb is 
responsible for activating the Pol II polymerase for transcription.  While other Pol III 
promoters have been explored the U6, H1, and 7SK are the most frequently used in 
shRNA expression plasmids.         
 
Livestock Pol III Promoters 
RNAi technologies in animal agriculture based research could be a valuable tool to 
better understand basic physiology and molecular pathways.  It is particularly beneficial 
because creating knockout livestock models to study a molecular pathway is impractical 
and very difficult when compared to rodent models.   However, the majority of shRNA 
expression vectors to date has used either human or mouse promoters. While the mouse 
and human promoters are functional in livestock species; the use of species specific 
promoters to express a shRNA has been explored.  Thus far, bovine, porcine, and 
chicken Pol III promoters have been identified and characterized [59, 61-65].  When 
these promoters have been compared to the mouse or human counterparts sequence 
differences among key promoter elements have been reported.  In addition, some 
livestock promoters have been more effective than the human or mouse promoter in 
knockdown assays in vitro.  These previous experiments have shown that Pol III 
promoters from other species might be   better suited for RNAi based research projects.   
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RNAi applications in animal agriculture research could have many benefits.  Cattle are 
important in agriculture research as early embryo models, and for milk and meat 
production.  To determine if homologous Pol III promoters were advantageous in 
shRNA expression, bovine Pol III promoters were identified.  These promoters were 
transiently tested for their ability to express an shRNA resulting in the knockdown of 
EGFP in various cell lines.   The bovine Pol III promoters analyzed to date include: 7SK, 
U6-1, U6-2, U6-3 [59, 66].  The U6 promoters are unique because there are numerous 
copies of the U6 snRNA in the genome.   It is estimated within the human genome that 
there could be over 200 U6 genes, and to date 9 promoter regions have been identified.  
As a result, it can be assumed that these (U6-1,-2,-3) are probably not the only three U6 
promoter regions in the bovine genome-.  When the three U6 promoters were analyzed, 
two (U6-2, -3) resulted in a similar knockdown of EGFP and U6-1 was slightly less 
effective.  In addition, the bovine U6-2 and U6-3 shRNA expression plasmid were more 
effective at reducing fluorescent levels than the commercially available mouse U6 
expression plasmid pSilencer 1.0-U6 [66].  However, the bovine 7SK expression plamid 
resulted in the greatest knockdown almost 2-5 times better than the pSilencer 1.0-U6 in 
all of the cell lines utilized [59].  These cell lines included: Vero (monkey), L929 
(mouse), DF-1 (chicken), MDBK (bovine), and Hela (human).  As a result of this 
research, bovine Pol III promoters U6-2, U6-3, and 7SK were more efficient at 
expressing a shRNA in bovine cells than the commercially available pSilencer 1.0-U6.  
In conclusion, it appears that bovine Pol III shRNA expression vectors are a better 
choice for transient experiments using bovine cells.   
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Another livestock species where RNAi research could assist with a better understanding 
of physiology and enhance production is swine.  Three functional porcine promoters 
have been identified to date pY1, pY3, and pU6 [63].  The Y RNAs are small 
cytoplasmic RNAs that are components of the Ro ribonucleoprotein complex (RNP).  To 
determine the promoter strength shRNA expression vectors were made using the above 
mentioned promoters to drive expression of a luciferase targeting shRNA and reduction 
of luciferase activity was analyzed.  The most effective promoter was the U6 promoter.  
Its activity resulted in only about 5% luciferase activity (or 95% luciferase knockdown) 
when compared to the negative controls.  In addition, the cells using the Y1 promoter to 
express the luciferase targeting shRNA were observed to reduce luciferase activity by 
>85%. While not as effective with a range of 70-82% the Y3 promoter was still efficient 
at producing a functional shRNA.  In this study the promoters were not compared to 
mouse or human promoters, however, they are very effective and are a viable option for 
porcine based research.      
 
The chicken is a widely used livestock model for studies of vertebrate development and 
genenome function.  RNAi could prove to be very beneficial in these fields and many 
chicken Pol III promoters have been analyzed.  Currently, the chicken 7sk promoter and 
4 U6 promoters (annotated U6-1, -2, -3, -4) have been identified and analyzed for their 
ability to express an shRNA [62, 64, 65].  Previously, it was reported in other species 
that the species specific 7sk promoter is more efficient at expressing a shRNA than 
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currently available shRNA expression plasmids [59].  However, when the chicken 7SK 
was analyzed in chicken DF-1 cells, the pSilencer 1.0 U6 resulted in a slightly greater 
knockdown [62].  The chicken 7SK shRNA expression vector was able to achieve a 
>50% knockdown, and was concluded by the author to be a viable option for future 
RNAi research.  Two independent laboratories tested the chicken U6 promoters’ ability 
to express shRNAs targeting either the fluorescent protein EGFP or the Luciferase [64, 
65].  When targeting luciferase in chicken ovary cells (COV1), the positive control (a 
human U6 promoter) resulted in a 41% knockdown, while the 4 chicken U6 promoters 
resulted in a knockdown range of knockdown range of (47-26%).  The chicken U6-2 and 
U6-3 were the most effective at reducing luciferase activity.  When these promoters 
were used to target EGFP in DF-1 cells, U6-3 and U6-4 were the most efficient of the 
chicken Pol III promoters with a reduction of fluorescence approximately 55-60%.  In 
addition, these knockdown levels were comparable to the positive pSilencer 1.0-U6, 
62%.  Based upon these studies, the chicken promoters are comparable to commercially 
available promoters and can be effectively used in RNAi studies of chicken cells.            
 
Applications of RNAi 
RNAi has become a powerful tool utilized for research, pharmaceuticals, and 
agricultural advancements.  In the research field, the RNAi pathway is an effective quick 
alternative to creating loss of function mutants to study protein function, complex 
protein pathways, and functional genomics in both in vitro and in vivo studies.  In our 
25 
 
 
laboratory, we are utilizing the RNAi pathway to study the roles of DNA methyl 
transferases and histone modifiers in early embryo development.  Also, the first 
transgenic animal that our laboratory produced which expressed a shRNA was a prion 
knock-down goat fetus [6].  The laboratory is continuing research in transgenic animal 
development by targeting the endogenous protein myostatin, which is a muscle growth 
inhibitor protein that should result in transgenic animals with greater muscle mass.  In 
addition, we are also utilizing the RNAi pathway by developing animals or in vitro 
models that express shRNAs targeting livestock viral genomes (FMDV and Equine 
Infectious Anemia Virus).  The use of dsRNA as short-lived small-interefering RNA’s 
(siRNA) or constitutively expressed short-hairpin RNA’s (shRNA) are being explored as 
medicines to combat viruses like HIV and hepatitis, or utilized against macular 
degeneration and liver failure [45, 67].  In agriculture, RNA interference is being 
explored in crops as possible means for additional disease and pest resistance [68].  
RNAi has become a vital component to many different fields; however, effective dsRNA 
delivery systems have not been optimized for specialized uses. 
 
Retroviral Transgenesis  
Just as the utilization of the natural RNAi pathway has proven to be a powerful tool in 
research; the manipulation of retroviruses to introduce foreign DNA into target genomes 
has proven invaluable.  The use of recombinant retroviruses to shuttle DNA into the 
genome of early embryos was first used to make transgenic mice before being used to 
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develop transgenic livestock models.  Transgenic mice were made using the Moloney 
leukemia virus (MLV) to introduce its genome into all organs of the mouse by 
transducing 4-8 cell preimplantation embryos [69].  This was the first time that a 
gammaretrovirus infected a tissue it was believe to not be able to infect and was able to 
pass the transgene to subsequent offspring.  However, other research studies using 
similar early generation vectors found that after integration, majority of the transgenes 
were silenced during the embryo’s development [70].  Another disadvantage to the use 
of these early gammaretroviruses as a gene delivery system is that they can only 
transduce actively dividing cells; thus limiting their potential for in vivo gene delivery in 
nonproliferating cells [71].  To overcome this, Naldini et. al; 1996, developed a similar 
gene transfer system using components of the lentivirus HIV-1.    
 
Lentivirus 
Natural lentiviruses are a genus of the Retrovirdea family.  Some examples of these 
viruses include: Human immunodeficiency virus (HIV), Simian immunodeficiency 
viruses (SIV), and Feline immunodeficiency virus (FIV). They are unique in that they 
can infect dividing and non-dividing cells.  The lentivirus actively integrates large 
amounts (~10 kb) of DNA into the infected cell’s genome; thus, allowing long term 
expression of RNA. It is because of this unique trait that lentiviruses have been modified 
for gene therapies for in vitro and in vivo experiments [72, 73].   
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Process of Lentivirus Infection  
Lentiviruses are positive strand RNA viruses encased in an envelope.  They are 
approximately 80-100 nm in diameter.  The envelope contains glycoproteins that target a 
specific extracellular protein, i.e. HIV recognizes the glycoprotein CD4 on helper T 
cells, macrophages, monocytes, and dendritic cells.   Within the envelope is a cone-like 
protein based nucleocapsid that contains two RNA genomes, and proteins required for 
replication and integration.  Some of these proteins include reverse transcriptase, 
protease, and integrase (Fig. 3).  Once the envelope glycoproteins bind onto the cell 
receptors, they mechanically pull the virus to the cell membrane.  After fusion, a pore is 
created and the contents of the virus are extruded into the cytoplasm of the cell; while 
the envelope and capsid are degraded.  The RNA is first transcribed into a 
complimentary strand of DNA.  The single stranded DNA is reverse transcribed 
resulting in double-stranded DNA.  A sequence of the dsDNA is recognized by the 
integrase protein that shuttles the DNA through a nuclear pore.  Once inside the nucleus, 
the integrase makes a random nick in the cell’s DNA and ligates the viral RNA into the 
genome.  Unique to the viral genome that facilitate the integration and replication of the 
viral from the cells genome are long terminal repeats (LTR).   Each LTR contain a 
promoter recognition sequence (5’/3’ UTR).   During the reverse transcription, the 3’ 
LTR of the viral RNA becomes the 5’ LTR and is responsible for driving expression of 
the viral RNA after integration into the host genome.  Once integrated, the virus then 
uses the cell’s machinery to make more positive-strand mRNA and production of virus. 
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Fig. 3. Illustration of a Retrovirus (Lentivirus).  The retrovirus is protected by an 
envelope protein case that has glycoproteins that bind specific cell recptors on target 
cells.  Within the envelope, a cone-like capsid contains two positive-strand RNA 
genomes, as well as the viral proteins: reverse transcriptase, integrase, and protease.   
 
 
 
 
 
 
 
 
29 
 
 
Utilization of Multiple Vectors to Construct Recombinant Lentivirus 
Because of the highly infective nature of these lentiviruses, key components were 
removed from the viral genome to make them safe for use as gene delivery tools.  The 
essential components required to construct a recombinant lentivirus include the viral 
proteins: integrase, reverse transcriptase, transactivators, internal capsid proteins,  as 
well as the glycoenvelope proteins.  In addition the RNA to be packaged and integrated 
as DNA into the genome must be present.  Multiple vectors were developed to deliver 
the key components in trans after being transfected in a packaging cell line. The goal of 
these manipulations was to create a virus that would only go through the initial stages of 
infection, genome integration, and not replicate to produce additional infective viral 
particles.[8, 73].   
 
One of the vectors is commonly called a packaging vector provides all the key viral 
proteins required for packaging and integrating the viral RNA.   A packaging vector 
(pCMVΔR9) was created that used the CMV promoter drive expression of the viral 
genome.  However, key deletions were made to the HIV genome in the 5’ LTR 
packaging sequence and in the env gene.  In addition, the 3’ LTR of the genome was 
replaced in this vector with a polyadenylation sequence.  This modification added 
another safe-guard to decrease the chance that RNA encoding the viral proteins essential 
for packaging, reverse transcription, and integration from being included in the 
recombinant virus.  Over generations of developing this packaging vector, researcher’s 
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have systematically deleted genes of this modified HIV genome to determine the 
proteins essential for viral production and integration.  As a result, they determined the 
viral products Vif, Vpr, Vpu, and Nef were not required for effective packaging and 
integration transgene RNA and subsequently deleted from packaging vector 
(pCMVΔR8.9) [74].  The essential genes in the packaging vector are gag, pol, tat, and 
rev.  The gag gene encodes viral products essential to form the capsid of the 
recombinant lentivirus.  The other essential viral products, reverse transcriptase and 
integrase are encoded in the pol gene.  The two Tat proteins are transcriptional 
transactivators required to activate transcription from the 5’LTR.  The Rev protein binds 
the RRE sequence of the RNA and assists in the shuttling of RNA through the nucleus to 
the cytoplasm.  By minimizing the genes expressed from this packaging vector and 
deleting key components, only the proteins are expressed during the production of 
recombinant lentiviruses and the gene sequences should not be transferred after 
transduction.         
 
Another requirement for an effective gene delivery rlentivirus is an envelope that can 
readily bind many cell types.   To accomplish this, the vesicular stomatitis glycoprotein 
envelope (VSV-G) is utilized [75].  The envelope protein was also provided on a 
supplemental vector (pMDg) to limit the chances of replication competent escape 
viruses.  The advantage of using the VSV-G envelope protein is that its corresponding 
extracellular receptor is ubiquitously expressed in animal cells, including those typically 
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used for in vitro experiments [76].  Another advantage of the envelope is that it is 
durable and protects the virus from adverse conditions.  This quality is advantageous to 
maintain a high percent of infective recombinant viral particles when purifying by ultra-
centrifugation or other methods, and also enhances long term storage of the virus.  The 
utilization of the VSV-G envelope has enhanced the capabilities of recombinant 
lentiviruses for gene transfer.              
 
The final component requiredto produce replication incompetent lentivirusis the vector 
that provides the packaged RNA.  Within this RNA sequence are the specialized genes 
of interest that the researcher wants to integrate into the target cells genome.  These can 
include but are not limited to: fluorescent markers, antibiotic resistance, RNAi 
expression cassettes, exogenous proteins, inducible promoters, or other genes or DNA 
sequences of interest.   As a result, many varieties of vectors are available that can be 
packaged into a recombinant HIV-based lentivirus.  The majority of them share key 
features that facilitate transcription, packaging, and integration.  Flanking the specialized 
sequences are 5’ and 3’ LTRs.  The 3’ LTR has had a region deleted that is required for 
promoter recruitment and imitation of transcription [9].  This is important, because after 
infection the viral RNA is reverse transcribed into dsDNA and the sequence 
corresponding to 3’LTR is now the 5’ LTR.  As a result of this deletion, once integrated 
into the genome the LTR can not initiate transcription of the entire DNA sequence, thus 
further decreasing the chances of replication competent escape viruses.  In addition to 
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the LTRs, the vector has to have a packaging sequence specific to the rlentivirus genome 
being used in the packaging vector.  Most vectors also have a central poly-purine tract 
sequence (cppt) near the 5’ viral promoter region that enhances transduction efficiency 
[77].  Another cis-acting DNA element in the lentiviral vector is the woodchuck post-
regulatory element (WPRE).  It is cloned 3’ to the transgene near the polyA signal of the 
3’ LTR and enhances integration of the transgene [78].  These viral elements provided 
on the vector facilitate and enhance the integration of genes of interest to the researcher.                  
 
Researchers have continued to refine and diversify the viral requirements in this multi-
vector system.  The goal of this system was to provide the necessary proteins in trans 
that are required to create a recombinant lentivirus that integrates the packaged RNA but 
is unable to replicate after infection.  As a result of these manipulations, a very effective 
laboratory safe method of using viral mediated transgenesis of cells was developed. 
  
rLentiviral Vector Utilized in These Experiments 
In our laboratory, HIV-based lentiviral vectors are utilized as tools for long term 
expression of shRNAs targeting endogenous proteins and exogenous viral genomes.  
The lentiviral vector that was used for this research was called Nef-GT (Fig. 4). The 
integrated transgene contains the EF1α promoter for the expression of an mRNA 
sequence that encodes the fluorescent marker zsGreen and a mir30 based shRNA.  The 
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zsGreen is important to visualize transduction rates.  In addition, a human 
phosphoglycerate kinase (PGK) promoter drives the expression of an antibiotic 
resistance gene, neomycin, for selection of transgenic cells.  Also, Nef-GT contains all 
of the key viral components that allow it to be packaged and integrated into the genome.   
 
 
Fig. 4.  Nef-GT mir-30 Based shRNA Lentiviral Expression Vector.  Transgene has dual 
opposing Pol II promoters.  Elongation Factor 1 α promoter is responsible for driving the 
fluorescent marker zsGreen and the mir30 based shRNA sequence in the same transcript.  
The Phosphoglycerate Kinase (PGK) promoter is responsible for the expression of the 
antibiotic resistance, G418 selection gene, and zeocin resistance as well.   
 
 
Different Promoter’s Potential for shRNA Expression Following a rLentivirus 
Transduction   
Recombinant lentiviruses have been the delivery system of choice for long-term, low 
cost dsRNA expression where protein knockdown is desired by the RNAi pathway.  
During the search for optimal promoters in vector mediated shRNA delivery systems, 
Pol III promoters were initially explored.  They are ideal for expression of precise short 
RNA sequences because of their specific transcriptional start and termination sequences. 
One of the first vectors developed used the human U6 small nuclear RNA promoter to 
express shRNAs targeting the firefly luciferase gene [79].  Since then, Pol III promoters 
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have been the primary choices for commercial companies for shRNA production.  The 
most widely used promoters for shRNA expression include the human U6 and human 
H1.  In addition, the human 7sk promoter has shown to express high levels of shRNAs in 
various cell types [80].  While these promoters have proven successful in various 
experiments, Lambeth et. al, 2006 reported that bovine U6-2 driven shRNA expression 
vector resulted in a greater knockdown of the target protein EGFP than its human U6 
counterpart in various cell types.  In addition, the bovine 7SK promoter based shRNA 
expression vector achieved the greatest knockdown in his experiments.   Due to these 
previous studies we decided to pursue species specific (bovine) Pol III promoters to 
express shRNAs in our lentiviral vector Nef-GT.  These unique bovine Pol III based 
shRNA expression vectors were used to create rlentivirus and introduce a shRNA 
targeting genes of interest into the bovine genome that could theoretically enhance 
production of the transgenic animal.   
 
Enhancing Livestock Production Characteristics 
Since the domestication of animals over 11,000 years ago, humans have had tried to 
increase the production of desirable traits.  Originally, this was done by selecting 
superior animals that exhibited the desired trait or traits, thus the development of 
selective breeding.  Some of these traits included: wool or coat production, increased 
meat production, increased rate of growth, better meat quality, increased milk 
production, better mothering instincts, and many others.  Unfortunately, while selecting 
for specific enhanced characteristics other important physiological and metabolism 
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pathways have been lost.  Over generations of livestock production, selective breeding 
has been effective at increasing the quality of the traits.   
 
Assisted Reproductive Technologies 
A limitation of selective breeding in animal agriculture has been the availability of 
superior genetics to a producer.  Before the mid-late 1900’s the producer was limited to 
either the best of the current herd or was required to purchase an animal to introduce 
new genetics.  As a result of the constrained distribution of genetics, the increased 
production of selected traits within breeds was limited.  Reproductive research and 
private industry have increased the availability of superior genetics by developing 
methods for safely collecting, storing, and transferring male and female gametes 
resulting in pregnancies [81, 82].  These assisted reproductive technologies (ART) 
facilitated the international distribution of superior genetics to producers for a cost far 
less than purchasing the animal.  In addition, ART allowed the producers to distribute a 
superior animal’s genetics and produce more offspring from this animal than traditional 
breeding practices.  However, even with all of these technology advancements the 
genetic gain of the desired traits has been reported to be 1-3% per generation.  But over 
the past 20 years with the common use of ART in animal agriculture a significant 
increase in important production characteristics has been observed.   
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Transgenic Livestock 
Alternative biotechnology tools have been explored to enhance a desired trait, or to 
introduce a new trait by creating transgenic livestock.  In 1982 transgenic mice were 
produced by microinjection of a gene construct into the pronuclei of a zygote.  This gene 
construct used the heavy metal inducible mouse promoter Metallothionein-I (MT) to 
express either rat or human growth hormone (hGH) [13].  The transgene was developed 
with the ultimate goal of significantly increasing growth and muscle development.   
These mice not only exhibited an increase in hGH mRNA, but also a significant increase 
in growth, up to 4 times greater than controls, and muscle mass.  In addition, these genes 
were passed through the germ line to subsequent generations.  Based upon this research 
a similar transgene was used to develop the first transgenic livestock (rabbits, sheep, and 
pigs) by microinjection into the pronuclei of a zygote [83].   These were the first reports 
proving that researchers could introduce foreign genes into the genomes of livestock.   
 
Further research efforts were pursued to increase the muscle mass by creating transgenic 
pigs. The following data was nicely reviewed by Pursel V. G., and Pinkert C. A., et al. 
1989.  Researchers used microinjection to develop transgenic pigs expressing transgene 
containing either hGH, bovine growth hormone (bGH), recombinant growth factor 
(rGF), or human insulin like growth factor-1 (hIGF-1).  Only about 8% of the 7000 
microinjected eggs resulted live births and of those only 7% were transgenic (40 
animals).  The economic importance of increasing the efficiency of weight gain, 
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decreased body fat, and overall better body composition provided incentive for this 
research.  These transgenic animals did not respond to the increased levels of growth 
hormone like the mice but a significant increase in average daily weight gain of 11-15% 
was observed.  In addition, when the bGH was used a 16-18% increase in feed efficiency 
was also observed.  These enhanced production characteristics were significant enough 
to have an economical impact in commercial herds, but the efficiency of producing these 
animals was not practical for commercial applications.     
 
In addition, numerous negative side effects were observed in these founder animals.  
They had a higher incidence of pericarditis, early onset of arthritis leaving some animals 
unable to walk, and peptic ulcers.  Also, many of the founder animals had impaired 
fertility, making the development of transgenic lines very difficult.  Also, the expression 
of an exogenous hormone for human consumption has risen many concerns not only 
among the public and the FDA[84].  As a result of these negative characteristics and the 
low success rates, the enthusiasm of utilizing transgenic livestock as everyday meat 
animals diminished.   
 
Transgenic livestock have been particularly beneficial for pharmaceutical production and 
human medicine.  The mammary gland naturally produces various proteins in high 
quantities for the nutritional support and development of young.  Researchers have 
harnessed these qualities by using mammary specific promoters to express recombinant 
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proteins and turned dairy animals into efficient pharmaceutical bioreactors.   Like many 
technologies that end up in livestock laboratories, this was first accomplished in a mouse 
model where transgenic mice were created that had produced the human tissue 
plasminogen activator protein driven by the murine whey acid promoter [85].  Shortly 
after this research was published, the potential of expressing recombinant human 
proteins in milk exploded in the academic and pharmaceutical research fields [86, 87]. 
The use of a transgenic livestock herd as bioreactors to produce pharmaceutical 
recombinant proteins has the potential to replace large facilities for tissue culture based 
bioreactors that are currently used to produce similar quantities of the recombinant 
protein. The first transgenic livestock were sheep that produced 63 g/l of α-1-antitrypsin 
in their milk [88].  In the following years, other mammary gland specific promoters were 
characterized for their ability to express a variety of recombinant human proteins 
important to the pharmaceutical industry.  Currently, some transgenic goats express a 
recombinant form of the human anti-clotting protein antithrombin, as well as the 
coagulation factors Factor VIIa, Factor IX, and Factor VIII[89].  These clotting proteins 
are important for the treatment of Type A hemophilia and are administered to patients to 
avoid episodes of excessive bleeding.  The low overhead once the transgenic animals are 
developed and the value of the products they produce have resulted in an important 
niche in the pharmaceutical field.  
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Another area of human medicine where the utilization of transgenic livestock has been 
explored is xenotransplantion.  Xenotransplantation is defined as; transplanting cells, 
tissues, or organs from one species into another.  Currently in the United States there are 
over 103,000 people waiting for transplants and 60% of the patients will die before they 
can be matched to a donor.  nsgenic pigs someday might be able to provide a viable 
option for some of these donors.  One of the first experiments testing the potential of pig 
organs for transplant was conducted in 1988.  A pig heart was transferred it into a non-
human primate.  Unfortunately in this early xenotransplantation experiment the organ 
only lasted hours. Other early xenotransplant organs were able to survive up to 5 days 
before being recognized as being foreign and rejected by the host’s immune system[90].  
 
Researchers have persisted and made significant strides in the development of transgenic 
pigs (1,3 galactosyl transferase gene knockouts or expressing the α(1,2) 
fucosyltransferase gene) that have delayed the rejection in some cases up to 6 months for 
a heart when combined with novel immunosuppressant agents[91-93].  Besides the 
rejection, another concern that has been raised is the possibility of porcine endogenous 
retrovirus (PERV) developing into a competent virus that infects organ recipients.  
Researchers have developed transgenic pigs expressing shRNAs targeting highly 
conserved sequences of these PERV[94].  In vitro studies showed a 73% reduction of the 
reporter plasmids expressing PERV proteins, in addition when the transgenic pigs were 
tested for the presence of PERV, none were observed by western blots or 
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immunefluorescent staining.  While there are still questions about the true potential of 
xenotransplantation as a means of extending a transplant patients life until a suitable 
donor can be found, it appears that specific transgenic knockouts coupled with anti-
rejection drugs and RNAi are all major advancements in research that might facilitate an 
important need for transgenic pigs.        
 
Methods to Produce Transgenic Livestock 
The use of transgenic livestock to enhance or introduce new production characteristics 
has been beneficial in many fields.  To continue these advancements the efficiency of 
producing animals must improve.  Initially, transgenic livestock were created by 
microinjection.  Microinjection involves injecting a chosen gene construct directly into 
the pronucleus of a fertilized ovum.  In these original studies microinjection resulted in 
very few live transgenic offspring.  About 2,000 pig and rabbit ovum were injected and 
transferred into recipients resulting in about 200 viable fetuses being developed per 
species and a range of 10.4% (pig) to 12.8%(rabbit) of them having the transgene 
incorporated into the genome.  However, the experiments involving the sheep only had 
1transgenic fetus from 1,032 ova injected and 73 fetuses collected.  Later research 
studies, reported similar low efficiencies ~2% of injected ova resulting in the production 
of transgenic livestock [83, 95, 96].  The efficiency of microinjection is too low for the 
practical applications of large scale transgenic animal production.    
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In the early ‘90’s another invaluable technology was developed that revolutionized 
transgenic livestock research, cloning.  The first offspring was born from nuclear 
transfer of cultured cells [97].  Previously, nuclear transfer has been successful in the 
multiplication of elite embryos either from the 16-cell, embryonic discs, or cultured 
embryonic cells [98, 99].  However, this was the first study where cultured adult cells 
successfully resulted in a live offspring.  As most pioneering studies the success rate was 
extremely low.  Out of 277 fused couplets only 29 morulas developed and 1 live 
offspring for an initial success rate of less than 0.4%.  Since then, advancements in the 
procedure have significantly increased the success rate of producing live cloned 
offspring in many different livestock species [100]. The increase success rate of cloning 
has been instrumental to the development of many transgenic livestock and animal 
research models which include but not limited to: sheep, goats, pigs, cattle, dogs, and 
cats [101].  Researchers can introduce the genes of interest into the genomes of an in 
vitro cell population and create single cell clonal populations.  These populations can 
then be tested for productive integration sites and subsequently used to create cloned 
transgenic livestock.  The advantage of this is that researcher knows that every embryo 
created is transgenic and has the gene of interest inserted.  Cloning also allows for 
selecting genetically uniform same sexed offspring.  While the success rate of creating 
transgenic clones is as low as 2%; it is still advantageous to use this method instead of 
pronuclear injection to create live offspring. 
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Recombinant lentivirus has been utilized to produce a variety of transgenic animals.  
Two primary methods that have been explored to create transgenic livestock are zona-
free embryos cultured in lentiviral particles, or injecting the particles into the 
perivitelline (PV) space of all embryos or ova followed by IVF.  The culturing of zona-
free or 2-cell embryos or blastocyst, in lentiviral particles and transferring them into 
recipient animals has successfully resulted in transgenic animals.  It was also observed 
that when blastocysts were cultured after hatching or without the zona pellucida that 
placenta specific expression was observed [102].  This localized transduction could be a 
powerful tool in helping better understand the maternal-fetal interface for reproductive 
physiology and human medicine.   The most common method to create transgenic 
animals using lentiviral transgenis is to inject the lentiviral particles into the PV space of 
early embryos or ova.  This method has shown far superior abilities to maintain embryo 
viability after manipulation (>70%) when compared to pronuclear injection (<18%) [10, 
103].  In addition, the pronuclear injection success rate of resulting in a live transgenic 
pig was 0.3-1.8%.  In comparison, the preliminary studies using lentiviral transduction 
of livestock species was near 80% efficiency for producing transgenic embryos and 50% 
of those embryos resulted in a live birth [10].   Overall, the use of lentiviral trangenesis 
has been a promising tool to introduce transgenes into germ or embryonic cells for 
various experiments and development of transgenic livestock.     
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When using rlentiviruses as gene delivery tools, one must be aware of the potential 
hazards and adverse affects.   The VSV-G glycoproteins of the rlentivirus envelope 
recognize an ubiquitously expressed mammalian cell receptor.  While this is great for 
lentiviral transgenesis in vitro, it presents a potential danger if not handled properly 
because it can readily infect majority of cells, including cells found within skin.  After 
the rlentivirus binds the cell, it can mediate the integration and subsequent expression of 
the transgene within the cell.  In addition, the envelope protein provides a strong 
protective surface for the virus and can survive for an extended period of time and still 
remain infective.  As a result, researchers must be very mindful when handling any 
equipment or fluids that could have been in contact with rlentivirus.  Besides the 
biosafety hazards associated with the use of rlentivirus as gene delivery tools, they have 
concerns the recombinant viral RNA enters the cell.  Even though many manipulations 
have been conducted to make them replication incompetent, and replication competent 
lentivirus have not been observed when using these later generation vectors [9, 104].   It 
is theoretically possible a replication competent lentivirus could develop [105].  There 
are also, concerns because of the unpredictable integration of the transgene.  Two main 
concerns associated with integration include gene disruption or trans-activation of 
oncogenes [106, 107].  rLentiviruses are excellent gene delivery tools, however when 
they are used, knowledge of the potential risks and concerns is required.   
 
 
44 
 
 
Research Objective 
The long term goal of the Reproductive Sciences Laboratory at Texas A&M University 
is to use molecular biology tools and technologies to advance the field of animal 
agriculture.  Currently, the laboratory is interested in enhancing production 
characteristics as well as developing disease resistance in livestock via transgenic 
technologies.  The laboratory routinely utilizes recombinant lentiviruses to deliver a 
transgene that can express one or multiple shRNAs depending on the target.  Preliminary 
research must be conducted to determine effective promoters to drive the expression of 
these shRNA in livestock species.  Previous research suggests that livestock Pol III 
promoters are equally or more efficient at expressing a shRNA when compared to their 
human or mouse counterparts [59].  The goal of this research study was to identify the 
bovine Pol III promoters 7SK, U6-2, and H1 and clone them into the lentiviral vector 
Nef-GT.  Then functionality and strength of the promoter to express a shRNA was 
analyzed both transiently and after integration into the bovine genome.  These studies 
are essential before the vectors can potentially be used to create transgenic livestock.   
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CHAPTER II 
MATERIALS AND METHODS 
 
Identification of Bovine Pol III Promoters 
Bovine Pol III promoters have been reported to be efficient at expressing simple shRNA 
complexes when transfected.  However, they have not been analyzed for their ability to 
express a mir-based shRNA, nor their functionality after integration into a bovine 
genome.  The goal of this research project was to determine the efficiency of bovine Pol 
III promoters to express a miRNA-30 based shRNA from the lentiviral vector Nef-GT.  
Three bovine Pol III promoters were selected for this research project, bU6-2, b7sk, 
bH1.  The bU6-2 promoter region was previously identified by Lambeth (2006) and the 
sequence (432 bp) is publically available on the National Center for Biotechnology 
Information (NCBI) website, accession number DQ150531.  In addition, Lambeth 
(2006) also identified and characterized a b7sk (695 bp) promoter region. The third 
promoter that we selected, bH1, was identified with the assistance of Dr. Kevin Wells, 
University of Missouri.  A 204 bp region directly upstream of the H1 ribonucleoprotein 
coding region on chromosome 10 was selected for our research study.   
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Developing Bovine Pol III Driven mir-30 shRNA Lentiviral Expression Vector  
Nef-GT mir-30 shRNA Expression Vector 
The lentiviral vector Nef-GT (Fig. 4) was a gift from Dr. Michael Golding at Cold 
Springs Harbor, NY. The Nef-GT vector contains many key elements that were desired 
in our experiments.  The integrated transgene utilizes the Pol II EF1α promoter to 
express the fluorescent marker zsGreen to visualize transduction rates, as well as a Mir-
30 based shRNA expression sequence.  The shRNA expression sequence contains the 
cloning sites EcoR1 and Xho1 to insert a designed shRNA. Between the zsGreen protein 
and the mir-30 shRNA expression sequence is the restriction site Not1.  This is the target 
site to insert the bovine Pol III promoter sequence.  In addition, the transgene also 
contains a neomycin resistance gene to for selection of transgenic cells.  Another key 
feature of this original vector is that between the shRNA insertion restriction sites there 
are only 6 nt.  This small byproduct is then easily removed during purification steps after 
the restriction digest, decreasing the chance of background ligations.  In addition, after 
the ligation of the PCR amplified shRNA into the Nef-GT, a restriction digest can be 
used to determine if the shRNA was inserted. As a result, fewer products have to be 
sequenced to confirm that the correct shRNA sequence is present in the vector.  Because 
of these qualities, the Nef-GT vector was manipulated to utilize the bovine Pol III 
promoter (7SK, U6-2, or H1) to express a mir-30 based shRNA.     
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PCR Amplification of bPol III Promoter 
The bovine Pol III promoters were PCR amplified from the bovine genome before they 
were inserted directly upstream of the mir-30 shRNA expression cassette of Nef-GT.  
Primers were designed specifically to amplify the promoter regions from the bovine 
genome. The 5’ (forward) primer was designed based either on the upstream region of 
previously published sequences; or for the bH1, a 21 bp region that would work well for 
primer annealing within the desired promoter range.  The 3’ (reverse) primer started at-1 
transcription site and included 19 bp upstream.  A single genomic DNA preparation 
obtained from a mix breed Bos Taurus Bos Indicus animal from Dr. James Womack’s 
lab, Texas A&M University was used as the template for the bovine Pol III promoters.  
The promoter sequence was initially amplified with the respective forward and reverse 
primer: bU6-2 A1, A2; b7sk A3, A4; bH1 A5, A6 (Appendix B. Table 3).  A high 
fidelity polyermase was used in the PCR master mix, which included 7% DMSO for 
genomic amplification.  Detailed protocols can be found in Appendix A.1.  The PCR 
products were subcloned into the pGEM Easy-T vector from Promega and grown in 
Stbl3 Escherichia coli (E. coli; Appendix A. 2, A. 3).  Plasmid DNA was collected for 
restriction enzyme test digestion, sequence confirmation, and long term product storage 
(Appendix A. 4).  Sequencing was performed by the Gene Technologies Laboratory at 
Texas A&M University using the internal T7 FWD primer sequence to confirm the 
products creating pGEM-bU6-2, pGEM-b7sk, pGEM-bH1.  
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PCR Mediated Insertion of Restriction Enzyme Sites to Bovine Pol III Promoter and 
Cloning into Nef-GT 
The pGEM-bPol III vectors were used as DNA templates in a PCR reaction that added 
restriction enzyme sites Not 1 on the 5’ end of the promoter and PsP0M1 on the 3’ end 
(Appendix A.1-4).  The following primers w/restriction sites (forward, reverse 
respectively) were used for bU6-2 B1, B2; b7sk B3, B4; bH1 B5, B6 (Appendix B. 
Table 3).  Two restriction sites were used because when digested with these restriction 
enzymes, the cut sites resulted in compatible cohesive ends and allowed the promoter to 
be inserted in the Not1 site of Nef-GT, which is directly upstream of the mir-30 based 
shRNA expression cassette.  Unique to this procedure, the Not1 site of the Nef-GT bPol 
III vector is maintained on the 5’ end of the promoter while the sequence on the 3’ end is 
not recognized by the Not1 restriction enzyme.  This technique allows future digestions 
of the Not1 site without disrupting the orientation of the inserted promoter.  Because the 
Not1 restriction enzyme is not very effective when the recognition sequence is near the 
edges of linear DNA product, the PCR products were inserted into the pGEM-Easy T 
vector creating pGEM-bU6-2+Not1/PsP0M1, pGEM-b7sk+Not1/PsP0M1, pGEM-
bH1+Not1/PsP0M1 (Appendix A.2-4).  Plasmid DNA was collected and digested 
sequentially to maintain 100% restriction enzyme efficiency and purified by ethanol 
precipitation between the two digestions.   The digested samples were run on a 1% 
agarose gel to separate the digested bovine Pol III promoter regions and gel purified 
(Appendix A. 5-7).  In addition, 3.2 ng of the Nef-GT vector was also purified via 
ethanol precipitation following Not1 digestion to maintain the sticky ends and quantity 
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of the DNA.   The DNA pellet was resuspended in ddH2O for a concentration near 100 
ng/ μl. 
 
The purified DNA products were electrophoresed on a 1.2% agarose gel and compared 
to the 2-log 1 kb Ladder (New England Biolabs) to confirm the quality and quantity of 
the DNA.  Based upon these results the ligation mix using Quick Ligase (New England 
Biolabs) was modified to have a 6:1 molar ratio of bovine Pol III promoter:Nef-GT 
(Appendix A. 8).  For the ligations, 150 ng of Nef-GT was used in the ligation reaction 
and the ng quantities of the respective bovine Pol III promoters (bU6-2 36 ng, b7sk 63 
ng, bH1 18 ng) were determined using the Biomath calculator available from the 
Promega website.  The ligations were transformed into Stbl3 cells (Appendix A. 3, 4.1, 
4.2, 8, 4.4, 4.5, 9, 10) and the Nef-GT bPol III plasmids were sequenced resulting in 
Nef-GT bU6-2, Nef-GT b7sk, Nef-GT bH1 (Fig. 5).   
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A. 
 
B. 
 
C. 
 
Fig. 5. Nef-GT bPol III mir-30 Based shRNA Lentiviral Expression Vectors. Transgene 
has dual opposing Pol II promoters.  Elongation Factor 1 α promoter is responsible for 
driving the fluorescent marker zsGreen.  The Phosphoglycerate Kinase (PGK) promoter 
is responsible for the expression of the antibiotic resistance, G418 selection gene, and 
zeocin resistance as well.  In addition each vector has a bovine Pol III promoter 
sequence directly upstream of the mir30 shRNA expression region, making unique bPol 
III shRNA expression cassettes.   A. Is a representation of Nef-GT b7sk, B. Nef-GT 
bH1, C. Nef-GT bU6-2.  
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Functional Analysis of Nef-GT bPol III Vector 
Short Hairpin RNA Design, Amplification, Ligation into Nef-GT bPol III  
Once the novel lentiviral bPol III mir-30 shRNA expression vectors were developed, a 
functional assay was performed.  To determine that the promoters could express 
functional a mir-30 shRNA a quantitative luciferase knockdown assay was utilized.  
Thus, two shRNAs were designed specific for this project, one targeting the luciferase 
mRNA and the other being a non-targeting shRNA control.  To assist with the shRNA 
design, the publically available web tool, RNAi Central website, hosted by Cold Spring 
Harbor was utilized.  The website used a computer algorithm to analyze the mRNA for 
the best shRNA target regions.  The program outputs the shRNA as part of a mir-30 
based shRNA stem-loop complex.  This stem-loop complex is unique in that it includes a 
Drosha recognition sequence and the loop sequence is based on the endogenous miRNA 
confirmation.  The luciferase mRNA sequence was entered into the computer algorithm 
to design shRNA’s.  The algorithm returned three possible targeting or positive control 
shRNA sequences.  The first option was selected that targeted 1308 bp to 1328 bp of the 
luciferase mRNA.  In addition, we used a previously designed shRNA sequence 
targeting the Foot and Mouth Virus as the non-targeting control (Appendix B. Table 4).    
 
The 97 bp oligo sequence corresponding to the stem loop structure containing the unique 
shRNA sequence was ordered from Integrated DNA Technologies.  The DNA was 
rehydrated to a 100 mM concentration with ddH2O and PCR amplified (primers S1, S2; 
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Appendix B. Table 3) to insert restriction enzyme sites for Xho1 and EcoR1 respectively 
on the 5’ and 3’ ends. (Appendix A.11)  The PCR products were ethanol precipitated and 
digested with EcoR1 and Xho1 restriction enzymes as well as the Nef-GT bPol III 
vector.  The digested products were ethanol precipitated and ligated into Nef-GT as 
described in Appendix A.12, 4.3, 5.2, 8) resulting in the vectors: Nef-GT bU6-2 Luc, 
Nef-GT bU6-2 NT; Nef-GT b7sk Luc, Nef-GT b7sk NT; Nef-GT bH1 Luc, Nef-GT bH1 
NT.   
 
Transient Luciferase Assay to Confirm Function of Nef-GT bPol III Vector 
The ability of the promoters to express a functional mir-30 based shRNA was initially 
tested using a transient transfection luciferase knockdown assay.  For this experiment, 
the vector’s ability to knock down the luciferase protein was analyzed.  The relative 
luciferase protein levels were quantified using the Stop n Glo Assay (Promega) and a 
luminometer.  The pGL3 (Promega) vector was used as the luciferase expression vector, 
and as a transfection control, the pRL vector (Promega) was used to express the Renilla 
luminescent protein.  In addition, for this in vitro preliminary experiment, human 
embryonic kidney cells (HEK) 293-T cells were utilized.  The cell culture media utilized 
in this experiment and subsequent cell culturing was DMEM/F12 (Invitrogen) 
supplemented with 10% fetal bovine serum (Invitrogen) and 1x concentration of 
Penicillin/Streptomycin (Invitrogen).  The experimental vectors that were transfected 
were: Nef-GT bU6-2 Luc, Nef-GT bU6-2 NT; Nef-GT b7sk Luc, Nef-GT b7sk NT; Nef-
53 
 
 
GT bH1 Luc, Nef-GT bH1 NT The ratio for the transient transfection was 1:10:5 of 
Renilla: Luciferase: Experimental Vector or 40 ng pRL: 400 ng pGL3: 200 ng Nef-GT 
bPol III Luc or Nef-GT bPol III NT.   To deliver the vectors into the HEK 293-T cells 
calcium phosphate mediated transfection was utilized (Appendix A.13).  The plasmids 
were allowed 48 hrs to produce their respective products before luciferase and renilla 
activities were measured with the Stop and Glo Assay (Appendix A. 14).  The 
measurements were made with a luminometer and then exported to an Excel file.   
 
Statistical Analysis of Relative Luciferase Activity 
The relative percent of luciferase activity was calculated by dividing the relative 
luciferase activity of the Luc targeting controls by the Null controls for that vector.  The 
relative percent of luciferase activity was then arranged to be exported into the statistical 
program JMP.  ANOVA was used to determine statistical differences among the group 
of samples.  In addition, the means were compared pairwise by a Student’s t-test.  This 
test determined if there was a statistical difference between the targeting Luc samples 
and to their respective Null control, as well as differences among promoter function.  
Finally, the data was reported as percent luciferase knockdown when compared to its 
non-targeting control.   
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Functionality of Nef-GT bPol III shRNA Transgene after Integration into Bovine 
Genome  
Development of Luciferase Expressing MDBK Cells 
The purpose of this experiment was to determine if the Nef-GT bPol III shRNA 
expression cassette was able to produce a functional shRNA after it was integrated into 
the cell’s genome.  For this experiment, the luciferase protein being targeted was 
expressed from the genome of the immortalized Madin-Darby bovine kidney (MDBK) 
cells.  The luciferase gene was inserted into the MDBK genome using the PEIZ+Luc 
recombinant lentivirus (Fig. 6; Appendix A.15 - 19, 21).  The integrated transgene has 
an EF1α promoter expressing the luciferase coding mRNA sequence followed by an 
internal ribosome entry site to express the zsGreen fluorescent protein. Following this 
transduction, the MDBK cell line constitutively expressed the luciferase protein and low 
levels of zsGreen.  As a result of these cells (MDBK+Luc) not having a selectable 
marker, the transgenic cells had to be sorted.  For the cell sorting, a flow cytometer was 
used with stringent high accuracy parameters.  Following the sorting, a population of 
>99% zsGreen positive MDBK+Luc cells were grown and maintained.  In addition, the 
luciferase activity for 8x10
8
 cells was measured in triplicate to calculate a background 
measurement.   
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Fig. 6.   rLentiviral Vector PEIZ Luc.  This vector utilizes the Elongation Factor 1 α 
promoter to express an mRNA sequence whose coding sequence is inserted into the 
multiple cloning site (MCS).  In addition the vector has a fluorescent green marker, 
zsGreen, that is expressed by an internal ribosomal entry site (IRES). 
 
 
Construction of rLentivirus 
To construct recombinant lentivirus in our laboratory, two other vectors are co-
transfected with the lentiviral vector Nef-GT (Fig. 7).  The packaging vector that we use 
in our system is pCMVΔR8.91.  The third vector we use is the VSV-G expressing 
plasmid pMDG.  These vectors are transfected by CaPO4 into human embryonic kidney 
293T cells at an approximate ratio of 3: 2: 1 (Nef-GT: pCMVΔR8.91:pMDG).  Twelve 
to fifteen hours later the media is replaced with fresh media.  The cells are then given 48 
hrs to produce recombinant lentiviruses that are present in the media.  The media is then 
collected and filtered through a .45 µm filter to remove cells and cellular debris.  This 
media containing the virus can either be used for transduction, frozen for future use, or 
the virus can be purified to make a high-titer viral preparation. 
 
 
 
5’ LTR EF1α Luc zsGreenIRES 3’LTR
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Transduction of MDBK+Luc Cells with bPol III mir-30 shRNA Recombinant Lentivirus 
To test bPol III promoter function after integration, the MDBK+Luc cells were 
transduced in a 6 well plate at 60% confluency with the bPol III based recombinant 
lentivirus (Nef-GT bU6-2 Luc, Nef-GT bU6-2 NT; Nef-GT b7sk Luc, Nef-GT b7sk NT; 
Nef-GT bH1 Luc, Nef-GT bH1 NT) (Appendix A.19).  Following transduction, the cell 
population was cultured and expanded until a fluorescent population of cells was able to 
be visualized.  The transgenic MDBK+Luc+Nef-GT bPol III cells were selected using 
250 µg/ml of G418 (Sigma) until a 100% Nef-GTbPol IIII population was observed and 
then they were maintained under selection.  The selected MDBK+Luc cell samples: Nef-
GT bU6-2 Luc, Nef-GT bU6-2 NT; Nef-GT b7sk Luc, Nef-GT b7sk NT; Nef-GT bH1 
Luc, Nef-GT bH1 NT, were measured for luciferase activity by using the Luciferase 
Assay kit (Promega; Appendix A.20, 16) for eight observations per sample.  To help 
normalize the data, 8x10
8
 cells were collected per observation.  Luciferase activity was 
measured and statistically analyzed as previously described.   
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Fig. 7.  Production of Recombinant Lentivirus.  A multi-vector system is used to 
construct recombinant lentiviral particles in our laboratory.  The pCMVΔR8.91 vector 
provides all of the essential viral proteins important for packaging and integration to the 
system in trans.  The pMDG encodes the VSV-G envelope protein.  Nef-GT provides the 
RNA to be packaged and ultimately reversed transcribed into a dsDNA transgene that is 
inserted into the target cells genome.  These vectors are transfected in an approximate 
ratio of 3:2:1 of Nef-GT:pCMV:pMDG.  Our current method of transfection is CaPO4. 
The media containing the transfection components is replaced after 12 hrs. 48 hrs later 
media is collected that contains the recombinant lentiviral particles. 
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CHAPTER III 
RESULTS 
 
Identification and PCR Amplification of Bovine Pol III Promoters 
Two previously described bovine Pol III promoters, bU6-2, b7sk, and the novel bH1 
promoter were identified for this project as promoters to drive the expression of a mir-
based shRNA.  The same primer sequences were used to successfully amplify the b7sk 
and bU6-2 promoters from a bos taurus/bos indicus mix breed genomic preparation [59].  
A bioinformatics approach was used to determine the location of the bovine H1 snRNA 
coding sequence and primers were designed to successfully amplify a 204 bp promoter 
sequence.  All of the promoters were cloned into the pGEM Easy TA-vector and 
sequencing confirmed successful amplification. 
 
Development of Lentiviral Bovine Pol III mir-30 Based shRNA Expression Vectors 
Bovine Pol III promoters were PCR amplified to introduce the restriction enzyme sites 
Not1 (5’-end) and PsP0M1 (3’-end) onto the promoters.  After restriction enzyme 
digestion and ligation, all three promoters were successfully introduced into the base 
vector Nef-GT; creating the empty lentiviral vectors Nef-GT bU6-2, Nef-GT b7sk, and 
Nef-GT bH1.   
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Confirmation of Nef-GT bPol III Vector Function with Transient Luciferase Assay   
To test the functionality of the bPol III shRNA expression vectors, a transient luciferase 
knockdown assay was used.  Two shRNA sequences (a targeting Luc control, and a null 
(NT) control) were developed and individually inserted into the control Nef-GT vector 
as well as each bovine Pol III vector;  creating the following vectors: Nef-GT bU6-2 
Luc, Nef-GT bU6-2 NT; Nef-GT b7sk Luc, Nef-GT b7sk NT; Nef-GT bH1 Luc,  
Nef-GT bH1 NT.  When the means were compared, each promoter Nef-GT, Nef-GT 
bU6-2, Nef-GT b7sk, Nef-GT bH1 that expressed the targeting Luc shRNA resulted in a 
range of percent luciferase activity between 31% and 22% (Table 1) or a 69-78% (Fig.8) 
reduction of luciferase activity (P <0.0001) when compared to the null control.  In 
addition, there was a significant difference of percent luciferase activity among the 
promoters expressing the Luc shRNA.  The Nef-GT b7sk promoter for this experiment 
was the least affective with a reduction of percent luciferase activity at 69% (P <0.0001).  
Furthermore, it was also the least effective in this transfection mediated luciferase assay 
when compared to all other vectors expressing the targeting Luc shRNA (p-value, 
<0.0001).  The Nef-GT vector (Pol II based EF1α promoter) was moderately effective at 
74% reduction of luciferase activity when compared to the other vectors, but was 
significantly lower than both the Nef-GT bH1 (P = 0.0111) and Nef-GT bU6-2 (P = 
0.0005).  When compared to all of the vectors, there was no difference observed between 
the two most effective promoters, Nef-GT bH1 and the Nef-GT bU6-2, with a 
knockdown of luciferase activity of 77% and 78% respectively.        
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Table 1  
 Relative Luciferase Activity in a Transient Luciferase Knockdown Assay Mediated by 
bPol III shRNA  Lentiviral Expression Vectors. The relative luciferase activity was 
calculated by dividing the promoter sample luciferase activity (Luc) by the null (NT) 
control activity per promoter set .  P <0.0001 signified by superscript letters. 
 
 
 
 
   
 
 
 
 
 
 
 
 
Vector Observations 
Relative  
Luciferase  
Activity 
Standard 
Error 
Nef-GT 12 0.2568
B
 0.0206 
Nef-GT b7sk 12 0.3146
A
 0.0186 
Nef-GT bH1 12 0.2328
C
 0.0273 
Nef-GT bU6-2 12 0.2248
C
 0.0474 
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Fig. 8.  Transient Luciferase Knockdown Using Nef-GT bPol III shRNA Expression 
Vector.  Relative percent knockdown of transient luciferase activity via transfected Nef-
GT bPol III vectors.  The luciferase knockdown was calculated using the relative 
luciferase activity.  P <0.0001 signified by superscript letters.   
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Confirmation of bPol III Promoter Function after Integration of Transgene in the 
Bovine Genome  
Once the bPol III based lentiviral vectors were proven effective at expressing a 
functional shRNA with the transient transfection.  The next experiment was to prove that 
the bPol III expression cassettes are functional after being integrated into the bovine 
genome.  To test their activity a MDBK cell line that expressed the luciferase protein 
was utilized and luciferase knockdown was analyzed.  The cells were transduced with a 
recombinant lentivirus containing transgenes for the following shRNA expression 
vectors: Nef-GT Luc, Nef-GT NT, Nef-GT bU6-2 Luc, Nef-GT bU6-2 NT; Nef-GT 
b7sk Luc, Nef-GT b7sk NT; Nef-GT bH1 Luc, Nef-GT bH1 NT.  Following Geneticin 
selection, specific to the shRNA expression cassette, the cells were lysed and luciferase 
measurements were recorded.  All of the samples expressing the targeting Luc shRNA 
resulted in a reduced level of activity (Table 2).  The range of knockdown for these 
transduced experiments were 37% to 73% (P <0.0001) (Fig. 9).  In addition, there were 
significant differences observed between all of the bovine Pol III promoters.  In this 
study, the bU6-2 was least effective, with a reduction of relative luciferase activity by 
37% (p-value <0.001).  The bH1 promoter was moderately effective at 46% (P <0.0001).  
The b7sk promoter had the greatest observed reduction of the bovine Pol III promoters 
with a knockdown of the luciferae activity by 72% (P <0.001).  The control Nef-GT Luc 
targeting vector had similar knockdown at 68% reduced relative luciferase activity.  
Surprisingly, in this experiment the integrated promoters had vast differences of activity 
but all were effective to some degree.     
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Table 2   
Relative Luciferase Activity of MDBK+Luc Cells after Integration of a Bovine Pol III 
shRNA Expression Transgene.  The relative luciferase activity was calculated by 
dividing the promoter sample luciferase activity (NT or Luc) by the non-targeting (NT) 
control activity per promoter set.  P <0.001 signified by superscript letters.  
 
 
 
 
 
 
 
 
 
 
 
 
Vector     Observations 
Relative  
Luciferase  
Activity 
Standard 
Error 
Nef-GT 8 0.3171
C 
0.0239 
Nef-GT b7sk 8 0.2755
C 
0.0199 
Nef-GT bH1 8 0.5352
B 
0.0987 
Nef-GT bU6-2 8 0.6343
A 
0.0216 
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Fig. 9.  Transduced Nef-GT bPol III shRNA Mediated Luciferase Knockdown Assay in 
MDBK+Luc Cells. Relative knockdown of luciferase activity in MDBK cells expressing 
luciferase following transduction of the control vector Nef-GT or Nef-GT bPol III, either 
expressing an shRNA targeting luciferase (Luc) or non-targeting shRNA (NT).   The 
relative luciferase knockdown was calculated dividing the Luc sample luciferase activity 
(NT or Luc) by the (NT) control activity of the respective promoter and converted to 
percent knockdown.    P <0.001 signified by superscript letters. 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
 
Use of bPol III Promoters to Express a mir-30 Based shRNA 
The most common commercially available Pol III promoters to express a shRNA are of 
mouse or human origin.  These promoter regions are highly conserved and are effective 
at expressing a shRNA in many cell types.. However, species divergence could have a 
role in the efficiency of the promoter in livestock models[64-66].  Differences in the 
efficiency of the b7sk and mU6 promoter to express a shRNA have been observed 
between species and cell types [59].  As a result of these observations, promoter 
optimization in agricultural animal cells is required.   
 
Previously, livestock based Pol III promoters have been identified and characterized in 
cattle, chicken, and swine for their ability to drive expression of a shRNA. The first 
livestock Pol III promoters to be characterized were the bovine and chicken U6 and 7sk 
[59, 62, 64-66].  Swine based Pol III promoters were also shown to be effective at 
expressing a shRNA[63-66]. When these Pol III promoter sequences were analyzed, 
differences in spacing and sequences of key enhancer and core elements were reported.  
Variation in spacing and sequence specificity of key Pol III promoter elements have 
been reported to change the efficiency of transcription from the genome or after transient 
transfection [108].  In these initial studies of characterizing the function of livestock Pol 
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III promoters to express a shRNA, the promoter strength was determined by transient 
transfection.  All of the reported livestock based Pol III promoters were functional to 
varying degrees at expressing a shRNA that resulted in a decrease expression of the 
fluorescent protein, eGFP.   
 
It is difficult to extrapolate how these promoters would function in a transgenic animal 
when initiating shRNA expression from the genome. When the promoter is driving 
expression of a shRNA from a plasmid, the promoter strength can be skewed because a 
greater number of active shRNA expression cassettes are present.  In addition, the 
conformation of the promoter in a plasmid is more accessible to the Pol III polymerase, 
As a result, a tranfected cell might be producing a far greater number of shRNAs than 
the threshold to observe a physiological affect. Where as a transgenic animal will have 
far fewer active shRNA expression cassettes.  Also, since these expression cassettes are 
integrated into the genome, the chromatin structure of the promoter region, as well as 
possible DNA methylation or other cellular silencing mechanisms can result in varying 
quantities of shRNA transcripts being produced [10, 109].  As a result, further research 
is required to quantify the strength of livestock Pol III promoters to drive shRNA 
expression from a genome.      
 
The goal of this project was to evaluate different bovine based Pol III promoters in our 
rlentiviral shRNA expression system for future research experiments.  Three different 
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bovine Pol III promoters (bU6-2, b7sk, bH1) were utilized to express a mir-30 based 
shRNA after being integrated in the bovine genome.  The study described in this work 
was the first to characterize and use the bovine H1 promoter to express a shRNA.    The 
bU6-2, b7sk, bH1 promoters were effectively incorporated into the lentiviral vector Nef-
GT resulting in the first bovine based mir-30 shRNA expression vectors.   These vectors 
were initially tested by a transient transfection based luciferase knockdown assay.  All of 
the promoters were highly effective. When compared to the bU6-2 and bH1 promoters, 
the b7sk promoter was the weakest promoter to drive expression of a shRNA.  This 
observation was in contrast to previous results that reported the b7sk to be the most 
active promoter in multiple cell lines. Although, this initial experiment to confirm 
functionality of the promoters was conducted in human kidney cells (293T).  Previously, 
when the b7sk promoter was used to express an eGFP targeting shRNA in a Vero cell 
line (monkey kidney epithelial) its ability to reduce fluorescence was significantly 
decreased when compared to other cell types [59].  Also, the b7sk promoter had variable 
knockdown of fluorescence in multiple cell types from 70% in Vero cells to >90% in 
bovine kidney cells.   These previous observations support a theory that the arrangement 
and sequence of the enhancer and the core elements of pol III promoters are important 
for the efficiency of the promoter in different cell types and species.  The variability of 
the individual promoter function observed in these experiments suggests that different 
promoters may be more effective depending upon cell or species of origin.  In our 
experiment, significant differences were observed between promoter efficiency and all 
bPol III mir-30 based shRNA expression vectors resulted in desired knockdown levels in 
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human 293T cells. The Nef-GT bPol III vectors exhibited that they can be effectively 
used transiently for in vitro studies.    
 
Further testing is required to determine if these bovine based rlentiviral vectors would 
express a functional shRNA in a transgenic animal.  The first step to address this long 
term goal was to determine the individual bPol III promoter’s ability to drive expression 
of a shRNA after being integrated into the bovine genome.  We were the first to quantify 
the function of these promoters after integration into a homologous cell line.  Significant 
differences were observed between promoter function after integration into a bovine 
genome.  In these experiments, the b7sk was the most effective of the three bPol III 
promoters we used.  Similar observations were reported when comparing the human 7sk 
and U6-1 promoters in vivo [110].  This preliminary experiment proved that the bPol III 
based rlentiviral vectors could produce functional rlentivirus and integrate its transgene.  
The transgene was also functional after random integration into the bovine genome.  In 
addition, the Nef-GT b7sk is the most efficient at reducing a target mRNA when 
expressing an shRNA from the genome of MDBK cells in vitro.    
 
It is unlikely that the reduced promoter activity observed in the MDBK+Luc cell 
populations produced from the transduction of Nef-GT bU6-2 Luc or Nef-GT bH1 Luc 
is a result of differences in integration of the transgene.  The lentiviral mediated 
introduction of transgenes results in random integration and within the cell population 
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there is assumed to be hundreds to thousands of different integration sites.  Initially, 
when fluorescence was observed 3-4 days post-trandsuction, a similar transduction rate 
was observed.  This observation suggests similar number of integrations per cell in each 
population.  After selection, the cell populations appeared to have similar levels of 
zsGreen expression, further supporting that a similar number of integrations were 
observed between the different Nef-GT bPol III transduced cell populations.  In addition, 
the random populations of MDBK cells were maintained and individual cells were not 
selected to make clonal populations.  As a result, the chances of integration number or 
location resulting in the significant differences observed among the bPol III promoters 
strength to express a shRNA resulting in decreased luciferase activity is highly unlikely.   
 
The orientation of the different components of the Nef-GT bPol III construct could have 
an influence on the varied promoter strengths we are reporting.  The expression of the 
zsGreen fluorescent protein is directly upstream of the bPol III expression cassettes.  The 
EF1α promoter recruits a Pol II polymerase to transcribe the zsGreen coding sequence 
and may potentially continue down the DNA sequence into bPol III promoter regions. 
Thus, the Pol II promoter might be interfering with the recruitment of the Pol III 
promoter that is responsible for the expression of the shRNA. The b7sk promoter 
sequence was the longest at 695 bp, where as the bU6-2 and bH1 were 432 bp and 204 
bp respectively.  The efficiency of the U6 promoter is dependent upon the upstream 
enhancer elements octamer element (OCT)  and SPH to stabilize the Pol III promoter for 
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transcription initation [108]  In both the b7sk and bU6-2, these elements are 
approximately 250 bp upstream of the transcriptional start site[59].  The extra sequence 
between the end of the coding region for zsGreen and these elements could be providing 
a buffer for the 7sk promoter.  While the bH1 promoter sequence is much shorter than 
the bU6-2, its unique modification of a compact promoter sequence could have an 
influence on its strength in this integrated transgene [111].  Further research is required 
differentiate between actual promoter strength or if the orientation of these components 
within the Nef-GT bPol III are influencing the efficiencies of these promoters after 
integration.    
   
As a result of these observations two conclusions can be made as a consequence of the 
post-integration activity of the bU6-2 and bH1.  First, further research in different 
experimental conditions or targets are required before their observed reduced activity 
can be confirmed in livestock models.  The other is that if this reduced activity is 
confirmed, they can still be useful to express shRNAs in experiments that analyze an 
animal’s or cell’s response to varying levels of reduced protein expression.  While the 
observations from this post-integration experiment were unexpected, we are able to 
conclude that b7sk promoter is highly effective after integration into the MDBK genome 
and coupled with previously reported data in other cell lines, this promoter is the best 
candidate to produce a transgenic animal expressing a single shRNA.                  
 
71 
 
 
The potential of using RNAi to alter an animal’s gene expression is highly dependent 
upon the promoter expressing the RNAi effector molecule, as well as the other 
components of the integrated transgene and location of integration.  Previous research 
has shown that both Pol II and Pol III promoters are highly variable depending upon the 
cell type and species [18, 59].  In addition, the composition of the transgene can result in 
variable expression.  Some exogenous gene sequences have been shown to be more 
readily silenced after integration into a genome [112-114].  The location of the 
integrated transgene in the genome can influence the active recruitment of the 
polymerase[109].  Therefore, one integration site might be expressing a greater number 
of shRNAs than another.  In addition, the integrated transgene can be influenced by 
chromatin remodeling if it integrates in a region that is variable between tissues[114, 
115].  Consequently, the effectiveness of a promoter to express a mir-based shRNA 
could be highly variable from animal to animal because of these potential variations of 
expression and low integration numbers associated with lentiviral transgenesis to create 
transgenic animals,  As a result, further research in producing live transgenic cattle is 
required to determine optimal Pol III promoters and transgene constructs for expression 
of a shRNA.  Based upon our results and the average of hundreds to thousands of 
integrations into a bovine genome we conclude that the b7sk Pol III is a viable option for 
expressing a mir-based shRNA in a transgenic bovid.        
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Conclusion 
The bU6-2, b7sk, and bH1 promoters were successfully incorporated into the lentiviral 
vector Nef-GT creating the first functional bovine based mir-30 shRNA expression 
vectors.   When these vectors were transfected, all of the bPol III promoters were very 
effective at reducing target protein levels by expressing a mir-30 based shRNA.  The 
strong promoter activity of Nef-GT and Nef-GT b7sk was maintained after integration 
into  the bovine genome.  With regards to the bU6-2 and newly characterized bH1 
promoters, further research is required to fully characterize their activity after integration 
in bovine genomes.  In conclusion, the b7sk promoter was the strongest promoter to 
express a mir-30 based shRNA after being integrated into the genome of bovine cells.  
We further conclude that the Nef-GT b7sk is the best option to continue research in 
further characterizing shRNA expression in transgenic cattle.   
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APPENDIX A 
 
A.1 PCR Amplification of bPol III promoter from Genomic DNA 
PCR Master Mix (50 ul rxn) 
Genomic Amplification Volume (µl)   Vector Amplification Volume (µl) 
10X buffer with MgCl2 5   10X buffer with MgCl2 5 
10 mM dNTP mix 1   10mm dNTP mix 1 
10 mM forward primer 1   10 mM forward primer 1 
10 mM reverse primer 1   10 mM reverse primer 1 
Dimethyl Sulfoxide (DMSO) 3.5   Vector DNA (100 ng) 1 
Genomic DNA (100 ng) 1   Polymerase 1 
Polymerase 1   ddH2O 40 
ddH2O 36.5   
 
PCR Program:  
1. 940C Denaturing step 5 minutes 
2. 940C Denaturing step 30 seconds 
3. 580C Annealing step 30 seconds 
4. 680C Extension step 30 seconds 
5. Repeat steps 2-4 29 times 
6. 680C Final Extension step 7 min 
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A.2 TA-Cloning PCR products into pGEM Easy   
1. 1  µl of Bovine Pol III Promoter PCR Product 
2. 1 µl of Vector (50 ng) 
3. 3 µl of H2O  
4. Mix Steps 1-3 Together  
5. Add 5 µl of 2x Ligation Buffer 
6. Add 1 µl of Ligase 
7. Briefly Mix by Pipeting 
8. Incubate at room temperature for 1 hr or overnight at 40C 
 
A.3 Transformation of plasmid DNA into Stbl3 Cells   
1. The Stbl3 cells were removed from -800C storage and thawed on ice 
2. 50 ul aliquots of the Stbl3 cells were placed in chilled and labeled 500 µl tubes 
3. Add 7 µl of ligated plasmid DNA (pGEM-Easy, Nef-GT bPol III, Nef-GT) 
4. Keep on ice for 20 min to allow plasmids to enter cells 
5. Heat Shock the Stbl3 Cells for 50 Sec. to trap the plasmid inside 
6. Chill on ice for 1 minute 
7. Add 300 µl of SOC media  
8. Incubate for 45 minutes at 370C 
9. Plate on 1% low-salt LB  agarose plates supplemented with Ampicilian (50 
µg/ml)  selection 
10.  Culture 370C overnight no longer than 18 hrs  
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11.  Check for colony formation 
 
A.4 Confirmation of Bovine Pol III PCR Product Insert in pGEM Easy-TA Vector 
A.4.1 Growth of Colonies for mini prep plasmid DNA extraction 
Following colony formation, they must be grown and the plasmid DNA removed to 
confirm the insert of the PCR product and used for subsequent sequencing.  Eight 
colonies were plucked from the plates and placed in 6 ml of low salt LB broth for 
incubation at 37
0
C overnight or again no longer than 18 hrs.  Five ml of the cultured 
cells were collected and plasmid DNA was collected with the Qiagen plasmid.  One 
ml of cultured cells were reserved for long term storage of plasmid at -80
0
C after 
correct sequence was confirmed by sequencing. 
 
A.4.2 Plasmid Purification (mini-prep) 
1. 5 ml of cultered cells were centrifuged at ~4,000 g for 10 minutes 
2. Supernatant was removed and pellet was dried by inverting collection tube 
3. 250 µl of P1 was used to resuspend the cell pellet and transferred to 1.5 ml 
microfuge tube 
4. 250 µl of P2 lysis buffer was mixed with the P1/cells 
5. 300 µl of N3 neutralizing buffer was added and tubes inverted 5-8 times to mix 
6. The tubes were centrifuged for 10 min at 13,000 g  
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7. Supernatant was placed in purification column and spun 1 min at 13,000 g 
8. Flow through was discarded  
9. 700 µl of PE was placed in the purification column and spun 1 min at 13,000g 
10.  Flow through was discarded 
11.  Purification column was spun 1.5 min at 13,000g to remove the alcohol and dry 
column 
12. 75 µl of ddH2O was added to the purification column and allowed to rehydrate 
column for 10 min 
13. The DNA was eluted from the column in the 75 µl of ddH2O by spinning for 1.5 
minutes at 13,000 g 
14. DNA was stored at 40C if it was being used in the near future or -200C for long 
term storage 
 
A.4.3 Double digestion of vector DNA  
1. 3 μl of 10x Buffer 3 
2. 1 μl of 5’ restriction enzyme 
3. 1 μl of 3’ restriction enzyme 
4. 5 μl of eluted DNA mini prep sample 
5. 20 μl of  ddH2O 
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6. Incubate at 370C for 1 hr 
Following restriction enzyme digestion, 20 μl of the reaction was run on a 1.2% agarose 
gel at 150 constant volts for approximately 20 minutes and visualized with an ultraviolet 
light. 
 
A.4.4 Sequencing of vector at gene technologies laboratory Texas A&M University 
We provided the vector and sequencing primer to the facility to let the experts run the 
amplifying and sequencing reactions.   
 
A.4.5 Long term storage of Stbl3 cells 
1. 850 µl of cultured cells were placed into labeled 1.5 ml microfuge tubes 
2. 150 µl of glycerol 
3. Briefly vortex to mix the two solutions 
4. Store at -800C until seeding of culture media for plasmid purification 
 
A.5 Two step double digestion of donor vector 
A.5.1 Initial single restriction digest 
1. 3 μl of 10x Buffer 4 
2. 1 μl of restriction enzyme 
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3. 5 μl of eluted DNA mini prep sample 
4. 21 μl of  ddH2O 
5. Incubate at 370C for 1 hr 
 
A.5.2 Ethanol precipitation of DNA 
1. Add 20 μl of ddH2O (up to 50 μl) 
2. Add 5 μl of 3M sodium acetate 
3. Add 150 μl of cold 200 proof ethanol   
4. Chill in liquid nitrogen for 30-45 seconds 
5. Spin at 16,000 g for 35 min 
6. Remove supernatant  
7. Rinse DNA pellet with 150 μl ice cold 80% ethanol  
8. Remove all ethanol and air dry for 10 minutes 
9. Resuspend DNA pellet in 26 μl of 650C ddH2O
*
  
10.  Heat at 650C for 10 minutes to fully dissolve DNA pellet 
*
 dependent upon future use of product: 26 µl for single restriction enzyme 
digestion, 25 µl for double restriction enzyme digestion, 30 µl for ligation 
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A.5.3 Single Restriction Enzyme Digestion Following Ethanol Precipitation  
1. Add 3 μl of 10x Buffer 3 
2. 1 μl Restriction Enzyme Not1 
3. Mix and incubate at 370C for 1 hr 
 
A.6 Single restriction enzyme digestion of receiving vector prior to ligation 
1. 3 μl of 10x Buffer 4 
2. 1 μl of restriction enzyme 
3. 3.2 μg of eluted Nef-GT (1 μg/ μl) 
4. 23 μl of  ddH2O 
5. Incubate at 370C for 1 hr 
 
A.7 Gel Purification of DNA from an agarose gel 
1. While visualizing the product over the UV light a scalpel blade was used to cut 
the section of agarose containing the respective band and placed in a labeled 1.5 
ml microcentrifuge tube 
2. 600 μl of Buffer QG was added to the tube and incubated at 550C for 10 minutes 
to dissolve the agarose and suspend the DNA in the solution 
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3. The Buffer QG was then placed in a purification column and spun at 13,000 g for 
1 minute 
4. The flow through was discarded  
5. 750 μl of PE buffer was added and spun at 13,000 g for 1 min 
6. The flow through was discarded  
7. The empty purification column was spun 1.5 min at 13,000g to remove the 
alcohol and dry column 
8. 30 µl of ddH2O was added to the purification column and allowed to rehydrate 
column for 10 min 
9. The DNA was eluted from the column in the 30 µl of ddH2O by spinning for 1.5 
minutes at 13,000 g 
 
A.8 Ligation Protocol for PCR product insert into receiving vector  
(6:1 molar ratio of donor vector: receiving vector) 
1. 1.5 µl (150 ng) of Nef-GT 
2. 2-3.5 µl of purified Pol III Promoter DNA 
3. ddH2O for total volume 5 µl  
4. 5 µl 2x ligation buffer 
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5. 1 µl Quick Ligase 
6. Incubate on bench top for 8 minutes 
7. Chill on ice at least 1 minute before transformation 
 
A.9 Test Digestion of Bovine Pol III Promoter Ligation into Not1 site of Nef-GT 
1. 3 µl of 10x buffer 3  
2. 1 µl of restriction enzyme Not1 
3. 1 µl of restriction enzyme Ecor1 
4. 7 µl of mini-prep DNA (Nef-GT+bPol III promoter) 
5. 18 µl of ddH2O 
6. Mix and incubate at 37oC for 1.5 hours 
7. Following restriction enzyme digestion, 20 μl of the reaction was run on a 1.2% agarose 
gel at 150 constant volts for approximately 20 minutes and visualized with an 
ultraviolet light. 
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A.10 Plasmid Purification using Qiafilter Plasmid Purification Midi kit 
1. Fresh or -800C stored Stbl3 cells were used to seed 150 ml of low-salt LB media 
2. Bacterial cells were pelleted by 6,000 g for 15 min at 40C 
3. Supernatant was removed and pellet was dried by inverting the collection 
container 
4. The bacteria pellet was fully resuspended in 4 ml of Buffer P1 
5. The cells were then lysed by that addition of 4 ml of Buffer P2 and mixed by 
inversion and incubated for 4-5 minutes 
6. The lysis reaction was neutralized and proteins and genomic DNA were 
precipitated out by the addition 4 ml of ice cold P3 buffer. 
7. The neutralized lysate was immediately transferred to the barrel of the QIAfilter 
Cartridge and incubated for 10 min on the bench top.  
8. During the incubation period the QIAGEN-tip 100 was equilibrated with 4 ml of 
Buffer QBT 
9. Following the equilibration, the precipitate was removed from the lysate by 
forced filtration and collected in the QIAGEN-tip 100  
10. Allow the cleared lysate to enter the resin and bind the DNA by gravity flow 
through 
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11. The resin filter was washed 2 times with 10 ml of Buffer QC by gravity flow 
through 
12.  The DNA was eluted in 5 ml of warm 650C Buffer QF  
13. To precipitate the DNA for a greater concentration, 3.5 ml of isoproponal was 
added  
14. The precipitated DNA was pelleted by centrification at 15,000 g for 30 minutes 
in 4
0
C 
15. The supernatant was removed and the DNA pellet was washed with 70% ethanol 
then centrifuged at 15,000 g for 30 minutes in 4
0
C. 
16. The supernatant was removed and the DNA pellet was allowed to air dry for 10 
minutes  
17. The dried DNA pellet was resuspended in 500 µl of warm 650C ddH2O 
18. Then the DNA was quantified using the Nanodrop-1000 
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A.11 PCR Master Mix for Amplifying shRNA  (50 ul rxn) 
1. 10X buffer with MgCl2 ………. 5 µl 
2. 10mm dNTP mix ……………... 1 µl 
3. 10 mM forward primer ……….. 1 µl 
4. 10 mM reverse primer …………1 µl 
5. Oligo DNA (150 ng) …….……1 µl 
6. Polymerase ……………….……1 µl 
7. ddH2O …………………….…. 40 µl 
 
PCR Program:  
1. 940C Denaturing step 5 minutes 
2. 940C Denaturing step 30 seconds 
3. 570C Annealing step 30 seconds 
4. 680C Extension step 30 seconds 
5. Repeat steps 2-4 29 times 
6. 680C Final Extension step 7 minutes 
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A.12 Digestion of PCR amplified shRNA 
1. 3 µl of 10 x Buffer 2 
2. 1 µl of Ecor1 restriction enzyme 
3. 1 µl of Xho1 restriction enzyme 
4. 25 µl of rehydrated ethynol precipitated PCR product 
5. Digest at 370C for 1.5 hours 
 
A.13 Transient Transfection of HEK 293-T for Stop n Glo Assay   
1. HEK 293-T cells were subpassed into a 6-well tissue culture plate and allowed to 
plate and grow to 70-80% confluence the morning before transfecting.   
2. For the transfection the following vectors and solutions were combined in a 1.5 
ml microfuge tube: 
a. 40 ng of Renilla 
b. 400 ng pGL3 
c. 200 ng Experimental Vector 
d. 12.6 µl of CaCl2 
e. ddH2O to 100 µl 
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f. Briefly vortexed to mix 
3. Drop wise 100 µl 2x Hank’s Buffered Saline Solution was added while mixing. 
4. A final 10 second vortex was used to mix and allowed to incubate at room 
temperature for 15 minutes 
5. The calcium phosphate solution with the vectors was applied to the individual 
wells of the HEK 293-T and dispersed randomly through the media by a 4 point 
cross rotation 
6. The cells were then washed the following morning (16 hours) and 2 ml of culture 
media was added 
 
A.14 Stop-n-Glo luciferase assay 
1.  100 µl of Lar II media was loaded into alternating wells of a 96 well reader plate 
2. 10 µl x 2 of each sample of cellular lysate was added to those wells  
3. The plate was mixed and incubated for 5 minutes 
4. The reading Gain and PMT were adjusted per plate to maximize the non-
targeting readings without maxing out   
5. The plate was read two times with a 2 min wait period between readings 
6. Then 100 µl of Stop n Glo media was added to each well to stop the luciferase 
activity and activate the Renilla luminescent protein  
7. The plate was mixed and incubated for 5 min 
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8. The plate was read two times with the same settings and a  2 minute wait period 
between readings  
9. The files were saved and exported into an excel file to be later statistically analyzed.   
 
A.15 Calcium phosphate transfection of single vector, PEIZ + Luc 
1. HEK 293-T cells were subpassed into a 6-well cell culture plate (________) and 
allowed to plate and grow to 70-80% confluence the morning before transfecting.   
2. For the transfection the following vectors were combined in a 1.5 ml microfuge 
tube: 
a. 400 ng PEIZ+Luc 
b. 12.6 µl of CaCl2 
c. ddH2O to 100 µl 
d. Briefly vortexed to mix 
3. Drop wise 100 µl 2x Hank’s Buffered Saline Solution was added while mixing. 
4. A final 10 second vortex was used to mix and allowed to incubate at room 
temperature for 15 minutes 
5. The calcium phosphate solution with the vectors was applied to the individual 
wells of the HEK 293-T 
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6. The cells were then washed the following morning (16 hours) to remove the 
transfection media and 2 ml of culture media was added 
 
A.16 Luciferase assay 
1. 100 µl of Lar II media was loaded into alternating wells of a 96 well 
luminometer reader plate 
2. 10 µl x 2 of each sample of cellular lysate was added to those wells  
3. The plate was mixed and incubated for 5 minutes 
4. The reading Gain and PMT were adjusted per plate to maximize readings without 
maxing out   
5. The plate was read two times with a 2 min wait period between readings 
6. The files were saved and exported into an excel file to be later statistically 
analyzed. 
  
A.18 Production of recombinant lentivirus   
1.  HEK 293-T cells were plated the morning of the transfection to be 80-85% confluent in 
a 100 mm pate by the afternoon.   
2.  For the transfection the following vectors were combined in a 1.5 ml 
microfuge tube: 
a. 6 ug of VSVg expression vector pMDG 
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b. 12 µg of Delta 
c. 18 µg of PEIZ+Luc 
d. 36 µl of CaCl2 
e. ddH2O to 300 µl 
f. Briefly vortexed to mix 
3. Drop wise 300 µl 2x Hank’s Buffered Saline Solution was added while mixing. 
4. A final 10 second vortex was used to mix and allowed to incubate at room 
temperature for 15 minutes 
5. The calcium phosphate solution with the vectors was applied to the HEK 293-T 
plates 
6. The cells were then washed the following morning (16 hours) and 6 ml of culture 
media was added 
7. Following the wash, the cells were allowed to produce the recombinant lentivirus 
for 48 hrs 
 
8. The media containing the lentiviral particles was collected and centrifuged at low 
speed 2,000 g for 5 minutes to pellet cellular debris 
9. The supernatant was then filtered through .45 micron filter and stored in FBS 
coated polypropylene tubes at 4
0
C 
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A.19 Lentiviral transduction of MDBK 
1. The MDBK cells were subpassed in the morning into a 6 well plate _____ to 
achieve a 60% confluency that afternoon in 2 ml of culture media 
2. 1 ml of media was removed and replaced with 2 ml of media containing 
PEIZ+Luc recombinant lentivirus  
3. 10 mM of Polybrene was added to the media to assist in the transformation 
4. The virus was given 24 hours to infect the MDBK cells before being washed and 
replaced with 2 ml of culture media 
 
A.20. Preparation of cells for luciferase assay of MDBK+Luc/+Nef-GT bPol III 
shRNA  
1. 1.  The culture media was removed and the cells were washed with 1x DPBS  
2. The cells were trypsinized and suspended in DPBS  
 
3. The cells were counted using a hemocytometer and the volume of 8x108 cells 
was determined.   
4. The cells were pelleted by briefly centrifuged at 800 G for 3 min 
5. The supernatant was removed and the cells were lysed with 100 µl of Lysis 
Buffer for 10 min  
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6. The lysed cell solution was collected in a 1.5 ml centrifuge tube 
7. The cellular debri was pelleted by a centrifucation of 8,000 g for 1 min 
  
A.21 Cell sorting of MDBK+Luc cells 
1. Population of 90% confluent transduced MDBK+Luc cells in a T75 flask were 
washed and trypsinized 
2. The cells were resuspended in growth media to neutralize the trypsin  
3. 3/5th of the cells were centrifuged to pellet the cells 
4. The supernatant was removed and the cells were resuspended as single cells in 3 
ml of 1X PBS solution 
5. To guarantee single cells were processed in the flow-cytometer, the suspended 
cells were filtered through a 40 micron filter.   
6. The single transgenic cells were then sorted in the flow cytometer using stringent 
high accuracy parameters 
7. The transgenic cells were sorted into 1x PBS 
8. The cells were collected by centrifugation and resuspended in growth media 
9. The cells were then plated in a T25 tissue culture flask and grown to populate a 
T75 tissue culture flask and maintained at 60-90% confluence 
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10. A population of the cells were frozen in 50% FBS and 5% DMSO  for long-term 
storage and future use 
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APPENDIX B 
Table 3. Primers Utilized for PCR Reactions 
Primer 
Name 
Description Sequence 
A1 5’ bU6-2 amplifying  CAGTAGTTGCGGGGATCAC 
A2 3’ bU6-2 amplifying  GCAGTTTTAGTATATGTGCTGCC 
A3 5’ b7sk amplifying  GGATGAGGAAGGAGCGTGAG 
A4 3’ b7sk amplifying  TCAACCCTGGCGATCAATGG 
A5 5’ bH1 amplifying  CGAACGCTGACGTCATCAGTC 
A6 3’ bH1 amplifying  CCGCACGCAAATAGCACTT 
A7 5’ zsGreen amplifying  GCA ATGGCCCAGTCCAAGCACGG 
A8 3’ zsGreen amplifying  GCAGATGCGATCCTTAGGGCAAGG 
A9 5’ Luciferase amplifying  ATGGAAGACGCCAAAAACATAAAG 
A10 3’ Luciferase amplifying  TTTTACCACATTTGTAGAGGTTTTA 
B1 5’ bU6-2 + Not1 RE GATGCGGCCGCTAAGTAGTTGCGGGGAT
CAC 
B2 3’ bU6-2 + PsP0M1 RE CAGGGCCCTTTTAGTATATGTGCTGCC 
B3 5’ b7sk + Not1 RE GATGCGGCCGCGGATGAGGAAGGAGCG
TGAG 
B4 3’ b7sk + PsP0M1 RE CAGGGCCCTCAACCCTGGCGATCAATGG 
B5 5’ bH1 + Not1 RE GATGCGGCCGCAACGCTGACGTCATCAG
TC 
B6 3’ bH1 + PsP0M1 RE CAGGGCCCCACGCAAATAGCACTT 
B7 5’ zsGreen + BamH1 GCAGGATCCATGGCCCAGTCCAAGCACG
G 
B8 3’ zsGreen + Not1  GCATGCGGCCGCGATGCGATCCTTAGGG
CAAGG 
B9 5’ Luciferase + EcoR1 CGGAATTCCCATGGAAGACGCCAAAAAC
ATAAAGAAA 
B10 3’ Luciferase +Xba1 GCTCTAGAATTACACGGCGATCTTTCCG
CCCTT 
S1 5’ shRNA oligo amplifying  
(5’ mir30 Xho1 primer) 
CAGAAGGCTCGAGAAGGTATATTGCTGT
TGACAGTGAGCG 
S2 3’ shRNA oligo amplifying 
(3’ mir30 EcoR1 primer) 
CTAAAGTAGCCCCTTGAATTCCGAGGCA
GTAGGCA 
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Table 4. shRNA Sequences 
Name Target Sequence 
Luc, 
Targeting 
Luciferase TGCTGTTGACAGTGAGCGCCCGCCTGAAGTCTCTGATT
AATAGTGAAGCCACAGATGTATTAATCAGAGACTTCAGGC
GGTTGCCTACTGCCTCGGA
a 
NT,  
Non-
targeting 
Foot and 
Mouth 
Virus 
TGCTGTTGACAGTGAGCGCCCTGTCGCTTTGAAAGTGA
AATAGTGAAGCCACAGATGTATTTCACTTTCAAAGCGACA
GGTTGCCTACTGCCTCGGA
a 
 
a
mRNA targeting siRNA 22 bp sequence in bold, and complimentary sequence is in 
italics.  
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